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ABSTRACT
Hematopoiesis is maintained by a proper balance between self renewal and multipotent
differentiation of the hematopoietic stem cells (HSC). Acute myelogenous leukemia (AML) is
characterized by the blockage in the differentiation of HSC, while self renewal and proliferation is
preserved. It is important to understand the mechanisms involved in the inhibition of hematopoietic
differentiation and maintenance of the HSC state in order to develop better therapies for AML. In these
studies I have explored the role of Hsp90, omega-3 fatty acids and YB-1 in hematopoietic
differentiation. EML, a hematopoietic precursor cell line, was used as a model for the hematopoietic
system in these studies. My preliminary data showed the activation of Wnt signaling upon inhibition of
Hsp90 in EML cells. This data suggested the involvement of Hsp90 in the regulation of Wnt signaling
in EML cells. Moreover, my initial data with fatty acid studies indicated that omega-3 fatty acids could
affect Wnt signaling in EML cells. Unfortunately, further progression of both these studies was marred
by variability in my data. In my latest study, I have identified YB-1 as a marker involved in the
maintenance of the hematopoietic stem cell state. YB-1 was found to be highly expressed in the EML
cell line and in the mouse bone marrow-derived HSC and myeloid progenitor cells. In addition, YB-1
expression was downregulated during myeloid differentiation in retinoic acid (RA) and granulocyte
macrophage colony stimulating factor (GM-CSF) treated EML cells, as well as in the granulocytes
derived from mouse bone marrow. Further, abnormal YB-1 expression was observed in myeloid
leukemic cell lines. Knockdown of YB-1 expression and arsenic trioxide treatment (As2O3) in
erythroleukemic, K562 cell line resulted in apoptosis and inhibition of cell proliferation. Most
importantly, these treatments led to the induction of megakaryocytic differentiation in these cells.
Overall my data suggests that increased expression of YB-1 in the leukemic cells contributes to the
leukemic cell properties by promoting cell proliferation, cell survival and blocking cell differentiation.
Thus, YB-1 could be a potential target for therapy in myeloid leukemia.
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CHAPTER One: INTRODUCTION
Hematopoiesis
Hematopoietic stem cells (HSC) are the stem cells that give rise to blood and immune
cells. They are ultimately responsible for the constant renewal of blood as billions of new blood
cells are produced every day. Hematopoietic stem cells have the capability of self renewal and
multi-potent differentiation, and hematopoiesis is maintained by a proper balance between the
two. Hematopoietic stem cells give rise to multipotent committed progenitors - common
lymphoid progenitors (CLPs) and common myeloid progenitors (CMPs) (Figure 1.1). These
multipotential committed precursors are highly proliferative and express receptors for specific
growth and survival factors- the colony stimulating factors (CSF). The CMPs further produce
megakaryotic/erythroid progenitors (MEPs), which differentiate into erythrocytes and platelets;
and granulocye-monocyte progenitors (GMPs), which then produce granulocytes and
monocytes. The CLPs give rise to mature T lymphocytes, B lymphocytes and natural killer
cells (Kaushansky et al., 2006; Tenen, 2003).
The production of hematopoietic cells is under the tight control by a group of
hematopoietic cytokines. Among these, the most important regulators of HSC maintenance are
stem cell factor (SCF), and thrombopoietin (TPO). Receptors for TPO and SCF, c-Mpl and cKit, respectively, are both expressed on the surface of HSCs. SCF is expressed constitutively in
bone marrow (BM) stromal fibroblasts and endothelial cells and is essential to the survival,
proliferation and differentiation of HSCs (Broudy, 1997; Hartman et al., 2001). Administration
of a neutralizing antibody against c-Kit in mice led to the depletion of all progenitor cells in two
days, indicating the role of SCF in HSC maintenance (Ogawa et al., 1991).
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Figure 1.1. A general model of hematopoiesis. Blood-cells are produced from a hematopoietic
stem cell (HSC), which can undergo either self-renewal or differentiation into a multilineage
committed progenitor cells These include common lymphoid progenitor (CLP) and common
myeloid progenitor (CMP). CMP further divides to give rise to more differentiated progenitors,
committed to granulocytes and macrophages (GMs), and megakaryocytes and erythroid cells
(MEPs). CLP produces progenitors committed to T cells and natural killer cells (TNKs) and B
cells (BCPs). Successive division and differentiation of these progenitors give rise to fully
differentiated cells-B cells, NK cells, T cells, neutrophils, eosinophils, basophils, monocytes,
platelets and erythrocytes. Different cluster of differentiation antigens (CD) and markers
expressed on the surface of each cell type are shown in blue. NK cells (NKPs), T cells (TCPs),
granulocytes (GPs), monocytes (MPs), erythrocytes (EPs), megakaryocytes (MkPs).
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Mice with loss-of-function mutations in TPO or c-Mpl have a decrease in the number
of HSC that can repopulate the bone marrow. Further, there is reduction in the expansion of
HSCs that occurs after bone marrow transplantation. This suggests that TPO plays role in
promoting the survival and the expansion of HSCs.
Myeloid cell development involves the interaction of various cytokines in the survival,
proliferation and differentiation of myeloid progenitors (Figure 1.1). Interleukein-3 (IL-3), SCF
and TPO are involved in the formation of MEP from CMP. The differentiation of MEP into
megakaryocytes or erythrocytes depends on the presence of TPO or erythropoietin (EPO). CMP
give rise to GMP in the presence of granulocyte-macrophage colony stimulating factor (GMCSF). Differentiation of these committed progenitors into the granulocyte lineage or monocyte
lineage requires granulocyte colony stimulating factor (G-CSF) or macrophage colony
stimulating factor (M-CSF), respectively (Kaushansky et al., 2006).
Apart from cytokines, transcriptions factors are also thought to play critical role in
regulating normal hematopoiesis. These include lineage-specific factors and non-specific
transcription factors. The lineage-specific transcription factors are differentiating factors such
as PU.1, CCAAT/enhancer binding protein α (C/EBP α) and GATA1, affecting only small
number of related lineages. The non-lineage-specific transcription factors such as AML1 and
SCL are involved in almost all lineages. Disruption of acute myeloid leukemia (AML1) or stem
cell leukemia (SCL) affects formation of the entire blood cell lineage, as these transcription
factors function at the pre-hematopoietic stem cell stage (Tenen, 2003; Rosenbauer and Tenen,
2007). Expression of PU.1 is considered one of the earliest events favoring HSCs to lineage
commitment. PU.1 and GATA-1 are co-expressed in CMPs but their mutually exclusive
expression coincides with further commitment to either granulocytic/monocytic or
megakaryocytic/erythroid

differentiation

(Zhu
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and

Emerson,

2002).

In

erythroid/megakaryocytic leukemia cell line, K562 ectopic expression of PU.1 led to their
differentiation into granulocytes and monocytes, instead of megakaryocytes upon Ras pathway
activation. Further, overexpression of GATA-1 in granulocytic progenitor 32D cells redirects
them to megakaryopoiesis (Matsumura et al., 2000).
Disruption of this transcription factor function can interfere with the normal cellular
differentiation and lead to leukemia. Leukemia is characterized by a terminal differentiation
block of hematopoietic cells while the self renewal and proliferation is preserved.
Understanding the pathways by which transcription factors regulate differentiation is important
to developing improved treatments for hematological malignancies including leukemia.

Acute myelogenous leukemia
Various hematological abnormalities including myelodysplastic syndrome arise from
the dysregulation of the hematopoietic process. Myelodysplastic syndrome (MDS) is a
preleukemic state which involves the ineffective production of the myeloid cells. In one third of
patients with MDS, the disease transforms into acute myelogenous leukemia (AML), usually
within months to a few years. Leukemia comprises 33% of childhood cancers and is the most
prevalent cancer in the children. Among different types of leukemia, AML is the most common
leukemia diagnosed in infants with a five-year survival rate of 22.6% (Surveillance
Epidemiology and End Results, NCI). AML is characterized by bone marrow infiltration of
abnormal hematopoietic precursors and resulting disruption of normal production of red blood
cells, white blood cells, or platelets. It is diagnosed based on the presence of >30% immature
and functionless cells called blasts in the bone marrow and peripheral blood. Symptoms in most
patients arise from disruption of normal blood component production and include fatigue,
anemia, bleeding and bruising (thrombocytopenia), and fever with or without infection.
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Transcription
factor

Frequency in
AML

RUNX1–ETO
(t(8;21))

12–15%

CBFβ–MYH11
(inv16)

8–10%

PML–RARα
(t(15;17))

6-7%

MLL fusions
(t11q23)

4-7%

C/EBPα

7-9%

GATA1

Nearly 100% in
AMKL
associated with
Down’s
syndrome

PU.1

<7%

RUNX1

9%

Table 1.1. Examples of transcription factor mutations in patients with AML.Abbreviations :
AML, acute myeloid leukaemia; AMKL, acute megakaryoblastic leukaemia; CBFβ, corebinding factor-β; C/EBPα, CCAAT/enhancer binding protein-α GATA1, GATA-binding protein
1; MLL, mixed lineage leukaemia; PML, promyelocytic leukaemia; PU.1, transcription factor
encoded by SPI1; RARα retinoic acid receptor-α; RUNX1, runt-related transcription factor 1.

Chromosome aberrations are detectable in the leukemic blasts of approximately 55% of
adults with AML. Aberrant transcription factor activity in AML is associated with acquired
chromosomal translocations that result in oncogenic fusion products such as RUNX1–ETO
t(8;21) CBFβ–MYH11; Inv16, MLL (mixed lineage leukaemia; t(11q23) and PML–RARα
(promyelocytic leukaemia–retinoic acid receptor-α; t(15;17) (Table1.1). These chromosomal
changes have been recognized as the most important prognostic factor for achievement of
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complete remission, risk of relapse, and overall survival (Döhner and Döhner, 2008). Several
mutations that have been identified in genes such as C/EBPα GATA1, NPM1, FLT3 and c-Kit
and are associated with poor prognosis in AML (Rosenbauer and Tenen, 2007). Mutations in the
GATA1 gene that results in the formation of a truncated GATA1 protein with altered
transcriptional function occurs in acute megakaryoblastic leukemia (AMKL) affecting patients
with Down syndrome (Wechsler et al., 2002).
Stress response
Stress induced by change in temperature leads to a complex program of gene
expression and adaptive response. These cell stress responses are of great interest both to basic
biology and to medicine. The ability to survive and adapt to thermal stress appears to be a
fundamental requirement of cellular life, as cell stress responses are ubiquitous among both
eukaryotes and prokaryotes. Increase in temperature can result in a heat shock response and can
lead to the production of heat shock proteins (Hsp), while a decrease in temperature induces a
cold shock response resulting in cold shock proteins. Heat and cold shock responses are both
involved in inhibition of cell growth and reduction in protein synthesis. Depending on the
intensity of the exposure both heat and cold stress can lead to the activation of the apoptotic
program and, in the extreme cases, necrosis (Sonna et al., 2002).
New approaches are emerging in order to find therapies for AML. Some of these
approaches address the role of stress proteins in cancer. Cancer cells exist in a state of stress
and rely upon stress related proteins for survival. Many malignant cells have constitutively high
levels of stress proteins that correlate with aggressive and resistant tumors, resulting in poor
prognosis. Thus, stress proteins have been identified as attractive targets for therapy in cancer.
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Heat shock protein 90 (Hsp90)
In 1962, investigators reported that heat induced a characteristic pattern of puffing in the
chromosomes of Drosophila (Ritossa, 1962). This discovery eventually led to the identification
of the heat-shock proteins (Hsp) or stress proteins whose expression these puffs represented. It
was found that brief exposure of cells to high temperature can provide protection from
subsequent larger increases in temperature, even when this increase would normally be lethal.
Increased synthesis of Hsp in Drosophila cells following stresses such as heat shock was first
demonstrated in 1974 (Tissieres, 1974). Later it was shown that the heat shock response is
ubiquitous and highly conserved in all organisms from bacteria to humans (Schlesinger et al.,
1982).
Hsp act as molecular chaperone by enabling protein folding and assist in protein
trafficking. Molecular chaperones are a ubiquitous class of proteins that play important roles in
protein folding and in the protection of cells from several stresses associated with the disruption
of protein structure including heat shock. Chaperones bind to and stabilize the unstable
conformation of another protein therby helping in its folding and assembly. One major function
of chaperones is to prevent both newly synthesized polypeptide chains and assembled subunits
from aggregating into nonfunctional structures (Hartl, 1996).
Hsp90 is a specialized molecular chaperone required for the stability and function of
numerous client proteins (substrate protein) that are mainly involved in signal transduction
pathways. In unstressed cells, Hsp90 accounts for 1–2% of total protein, but in response to heat
shock this increases to 4–6% of cellular protein. Hsp90 is distinct from other chaperone systems
as it does not fold non-native proteins but rather binds to substrate proteins at a later stage of
folding. It interacts with various protein substrates to assist in their folding and plays a critical
role during cell stress by repairing damaged proteins (protein refolding), or by degrading them
thus restoring protein homeostasis and promoting cell survival (Jolly et al., 2000). Moreover,
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Hsp90 is critical to the survival of the organism since the genetic knockout of Hsp90 is lethal in
mice (Voss et al., 2000).

Hsp90 isoforms and structure
Hsp90 is highly conserved and expressed in a variety of different organisms from
bacteria to mammals. There are five functional human genes which encode Hsp90 protein
isoforms. In mammalian cells, there are two or more genes encoding cytosolic Hsp90
homologues Hsp90α (inducible form) and Hsp90β (constitutive form) which are the result of a
gene duplication event (Csermely et al., 1998). Human Hsp90α shows 85% sequence identity to
Hsp90β (Chen et al., 2005; Chen et al., 2006). An important difference is that the Hsp90α form
readily dimerizes, whereas the β form does so with much less efficiency. Hsp90α is shown to
play a regulatory role in muscle cell differentiation of zebrafish while Hsp90β is required for
early embryonic development (Reviewed in Sreedhar et al., 2004). Recently another Hsp90
isoform has been identified, Hsp90N, which shares high sequence homology with the other two
Hsp90 isoforms, but lacks the N-terminal domain (Figure 1.2). It has been shown to be
associated with cellular transformation by activating Raf in rat F111 fibroblasts
(Grammatikakis et al., 2002). However, a later study reported the existence of this isoform to
be accidental and occurred due to chromosomal rearrangement in a single cell line (Zurawska et
al., 2008).
Two other isoforms include GRP94 in the endoplasmic reticulum and TRAP1 in the
mitochondrial matrix. GRP94 is glucose-regulated, induced by glucose starvation and is known
to participate in protein folding and assembly (Gupta, 1995). TRAP1 acts as a molecular
chaperone to retinoblastoma protein (Rb) during cellular stress. It possesses a unique LxCxE
motif which is involved in binding to Rb. This motif is absent in all other Hsp90 family
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members (Chen et al., 1996; Felts et al., 2000). There is still not much known about the
function of these two isoforms of Hsp90.

Structure of Hsp90
Hsp90 consists of four structural domains (Figure 1.2). A highly conserved N terminal
domain (NTD) which has an ATP binding pocket necessary for Hsp90 function. Various natural
and synthetic inhibitors of Hsp90 bind at this site.

Figure 1.2. Structure of Hsp90 and its various isoforms. There are four structural domains of
Hsp90. The N terminal domain (NTD) is highly conserved and has an ATP binding site. A
charged linker region connects the NTD with the middle domain (MD). This linker region is
absent in TRAP1. MD is involved in binding to client proteins. The C terminal domain (CTD)
is the dimerization domain and has TPR binding site where cochaperones such as HOP bind.
The TPR region is absent in TRAP1 and GRP94 has instead an endoplasmic retention site.
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With the exception of TRAP1 there is a charged linker region that connects the NTD
with the middle domain (MD). The MD is also involved in client protein binding. The Cterminal domain (CTD) is the dimerization domain. In eukaryotes, the CTD has the
tetratricopeptide repeat (TPR) motif recognition site (consisting of amino acids MEEVD), which
regulates ATPase activity (Wandinger et al., 2008). This region is responsible for the interaction
with cochaperones such as HOP (Hsp 70-Hsp90 organizing protein). The TPR binding site is
absent in TRAP1 while in GRP94 this is replaced with an endoplasmic retention site. While the
C-terminal domain provides for the constitutive dimerization of Hsp90, the N-terminal domain
undergoes transient dimerization driven by ATP binding (Prodromou and Pearl, 2003).
The protein folding activity of Hsp90 is regulated by the dynamic association of
various co-chaperones (Figure 1.3). Hsp90 dimerizes at its CTD to form a U shaped structure
such that the N terminal domain is available for protein interaction. Hsp 70 and Hsp 40 form a
complex with the client protein for delivery to Hsp90 (Mahalingam et al., 2009). Hsp90 binds
to the Hsp70 complex by the adapter protein HOP via the TPR domain which is present at the
CTD of both Hsp90 and Hsp70. This is described as the “open conformation’’. Recruitment of
ATP to the NTD of Hsp90 results in dimerization and a conformational change leading to the
formation of clamp around the client protein (Prodromou et al., 2003). This is referred as the
“closed confirmation” and results in the dissociation of HSP70/HSP40/HOP complex. Aha is a
cofactor that can bind and stimulate the activity of ATPase. Cdc37 and p23 are then recruited
which help in the stabilization of the client protein and facilitates ATP hydrolysis (Pratt and
Toft, 2003; Pearl et al., 2003). This complex assists in the conformational maturation of the
client and maintains the protein in an active state capable of exerting its function.

10

Figure1.3. The Hsp90 superchaperone compex cycle. The binding of a client protein to Hsp90
requires the co-operation of another chaperone, Hsp70 and its co-factor Hsp40. Hsp90 dimerizes
at its C-terminal end. Hsp70 and Hsp 40 form a complex with client protein for delivery to
Hsp90. Hsp70 complex binds to Hsp90 by an adapter protein (HOP), through the small helical
TPR domains which is present at the C-terminal end of both Hsp90 and Hsp70. Initiation of
ATPase activity by binding of cofactors like Aha results in a conformational change (clamp
formation) in Hsp90 such that it dissociates from the Hsp70/Hsp40/HOP complex. Cdc37 and
p23 then replace the original cochaperones to assist in conformational maturation of the client
protein and its activation. Inhibition of ATP-binding through Hsp90 inhibitors prevents client
protein maturation and results in degradation of these oncogenic proteins by the proteasome.
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Role of Hsp90 in cancer
Hsp90 protein is found to be overexpressed constitutively in various types of cancer
cells (Multhoff and Hightower, 1996). Hsp90 regulates the conformation, activity, function and
stability of client proteins. There are over 100 known Hsp90 client proteins that include
transcription factors and protein kinases involved in oncogenic signal transduction pathways.
Hsp90 is overexpressed in breast, pancreatic, lung, ovarian cancers (Ochel and Gademan,
2002). Moreover, Hsp90 expression is high in various leukemic cell lines and human acute
leukemia cells (Yu Fu et al., 1992). Recently, Hsp90 was reported to be overexpressed in AML
patients and was associated with poor prognosis (Flandrin et al., 2008). Thus, Hsp90 is the
principle molecular chaperone implicated in oncogenesis making it an attractive target for
cancer therapy.
Cancer cells are particularly sensitive to Hsp90 inhibition and the therapeutic
selectivity for cancer versus normal cells is based upon three main factors (reviewed in Pearl et
al., 2008). Firstly, according to the ‘oncogene addiction model,’ cancer cells exclusively
depend on a sensitive Hsp90 client protein that drives malignancy. Degradation of a specific
Hsp90 client has a greater impact on the cancer cells than in normal cells. For example,
degradation of mutant BRAF in a melanoma cell or Bcr-Abl in chronic myeloid leukemia
(CML) results in apoptosis and/or differentiation, whereas their degradation in normal cells
leads to little or no effect. Secondly, many oncoproteins are expressed in mutated forms in
cancer cells that are much more dependent on Hsp90 for their stability and activity than their
normal counterparts, e.g. Bcr-Abl, EGFR and BRAF. Thirdly, cancer cells become dependent
on Hsp90 to manage the cellular stress created by the oncogenic process and the hypoxia,
acidosis and nutrient deprivation of the tumor microenvironment (reviewed in Solit and Chios,
2008). In support of this hypothesis, Kamal et al. have shown that Hsp90 in tumor cells is
found entirely in an active complex with co-chaperones, whereas most Hsp90 in normal tissues
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resides in a free, uncomplexed, or latent state. Since the binding affinity of Hsp90 inhibitors is
higher for tumor derived Hsp90 than in normal cells it allows specific targeting of tumor cells
(Kamal et al., 2003).
Hsp90 inhibition results in proteasomal degradation of large number of oncogenic
client proteins which are involved in all the hallmark traits of cancer, including proliferation,
evasion of apoptosis, immortalization, invasion, angiogenesis and metastasis. Targeting Hsp90
may be beneficial as it has a combinatorial impact on multiple oncogenic pathways. In addition,
this combinatorial action should markedly reduce the opportunities for cancer cells to develop
resistance to Hsp90 inhibition.

Hsp90 inhibitors
Targeting Hsp90 with drugs has shown promise in clinical trials. Hsp90 inhibitors
cause the destabilization and eventual degradation of Hsp90 client proteins. Majority of Hsp90
inhibitors bind to the ATP pocket of Hsp90 and block the ATPase cycle that is essential for
Hsp90 function (reviewed in Taldone et al., 2009). Hsp90 inhibitors Geldanamycin (GA) and
Radicicol were discovered as natural products and originally isolated as antibiotics.
Geldanamycin (GA) is a benzoquinone ansamycin which binds to the ATP pocket of
the N-terminal domain of Hsp90 and inhibits the binding of ATP. This inhibition targets bound
client proteins for ubiquitination and proteasomal degradation leading to depletion of
oncoproteins and consequent cell-cycle arrest and apoptosis (Hostein et al., 2001). Later it was
found that GA is insoluble in water, unstable and exhibits severe hepatotoxicity. Therefore 17allylamino-17-desmethoxygeldanamycin (17-AAG) was developed to enhance the solubility
and therapeutic index of geldanamycin. 17-AAG is currently being used in animal models of
cancer and has progressed to clinical trials (reviewed in Taldone et al., 2009).
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Approximately one third of acute myeloid leukemias have activating mutations of
FLT3, which are associated with adverse clinical outcome. 17-AAG exhibits a potent activity
against leukemic cell lines, particularly those harboring a FLT3 mutation (Minami et al., 2002).
However a recent study reported the effect of 17AAG on a large scale of AML patients. In this
study, overexpression of Hsp90 was associated with poor prognosis and resistance to
chemotherapy in AML patients. Leukemic cells from the patients with higher Hsp90 expression
showed spontaneous growth in liquid culture and colony formation. In vitro exposure of
leukemic cells to 17-AAG resulted in inhibition of growth in liquid and clonogeneic cultures
and induced apoptosis (Flandrin et al., 2008).
Chronic myeloid leukemia (CML) is characterised by the BCR-ABL fusion gene,
which is a constitutively active cytoplasmic tyrosine kinase. Imatinib mesylate targets the ATPbinding site of the kinase domain of ABL and is being used to treat CML patients (Druker et
al., 2001). However, patients can develop imatinib resistance (Gorre et al., 2001). Heat-shock
protein 90 maintains BCR-ABL stability and function. Treatment of BCR-ABL resistant cells
with 17-AAG was shown to target BCR-ABL for degradation and to suppress cell proliferation
(Nimmanapalli et al., 2001). Furthermore, Hsp90 inhibitors have been used in combination
with histone deacetylase (HDAC) inhibitors to induce apoptosis and inhibit cell growth in both
imatinib-sensitive and resistant BCR-ABL cells (Rahmani et al., 2005).
Stress induced by exposure to low temperature in cells can produce cold shock proteins
which are involved in a cold shock response. The cold shock response is similar to the heat
shock response in terms of inhibition of growth and reduction in protein synthesis in cells.
However, the heat shock response is ubiquitous and highly conserved in all organisms from
bacteria to humans and Hsp function as a molecular chaperone or protease. Moreover, cold
shock proteins are found only in bacteria and function as an RNA chaperone (Matisumoto et
al., 1998). In eukaryotes, the homologous region to the bacterial cold shock proteins is found in
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the nucleic acid binding region of the cold shock domain (CSD) protein family (Kohno et al.,
2003).

Y Box protein (YB-1)
Y-box proteins are members of the cold shock protein family that contain a CSD which is
highly conserved during evolution. There are three Y-box proteins in human and mouse, two of
which are expressed in both somatic and germ cells (Table 1.2). Contrin in human and MSY2 in
mouse are germ cell-specific members of the Y-box protein family. The Y-box protein, YB-1
(p50 or dbpB) is the most extensively studied member which is ubiquitously expressed in various
tissues (reviewed Matsumoto and Bay., 2005).

Human

Mouse

Expression

YB-1/DbpB

YB-1/MSY1

Ubiquitous

DbpA

MSY4

Ubiquitous
(Abundant in heart,
muscle and testis)

Contrin/DbpC

MSY2

Germ cells

Table 1.2. Y-box proteins in human and mouse
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YB-1 expression, structure and function
YB-1 was originally identified as a transcription factor and was named because it binds to the Ybox (inverted CCAAT-box) sequence of the major histocompatibility complex class II gene
(Didier et al., 1998). The CSD of the vertebrate protein is 40% homologous with the cold shock
protein isolated from bacteria (Kohno et al., 2003).

Figure 1.4 The Structure and Functions of YB-1. YB-1 protein has three domains: Nterminal, cold shock (CSD) and C-terminal domains (CTD). The N-terminal is involved in
transactivation whereas the CSD is the most conserved domain and is important for RNA/DNA
binding. The CTD has basic and acidic amino acids referred as B/A repeats and mediates
protein: protein interactions. Cellular trafficking is regulated by the presence of a nuclear
localization signal (NLS) and a cytoplasmic retention site (CRS) in the C-terminal domain.

The human YB-1 gene is contains 8 exons and is located on chromosome 1p34 (Toh et
al., 1998).The mRNA is about 1.5 kb long and encodes a 43 kDa protein which has 324 amino
acids (Didier et al., 1988). YB-1 is broadly expressed throughout development. High levels of
YB-1 are present in human fetal tissues of heart, muscle, liver, lung, adrenal gland, bone marrow,
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kidney and brain. On the other hand, YB-1 transcripts are not detected or are expressed at a very
low level in many adult tissues (Spitkovsky et al., 1992). Expression level of YB-1 correlates
with the cell proliferation state (reviewed in Lu et al., 2005). Also, high levels of YB-1 are
detected in regenerating liver after tissue damage and the proliferating compartment of colorectal
mucosa (Ladometry and Sommerville, 1995).

Structure of YB-1
The YB-1 protein consists of three domains: the variable N-terminal domain, a highly
conserved cold shock domain (CSD) and the C terminal tail domain (CTD) (Figure 1.4). The Nterminal domain is rich in alanine and proline residues and is thought to be involved in transactivation. The CSD is the most evolutionary conserved nucleic acid-binding domain that binds
RNA, as well as single-stranded and double-stranded DNA. The CTD of YB-1 contains
alternating regions of basic and acidic amino acids, called B/A repeats or charged zipper, and
facilitates dimer formation. This region is suggested to mediate protein–protein interactions.
YB-1 has been shown to interact with a number of cellular and viral proteins that are involved
in various cellular processes. Cellular localization of YB-1 is controlled by the presence of a
cytoplasmic retention site (CRS) and a nuclear localization signal (NLS) in the CTD (reviewed
in Kohno et al., 2003; Wu et al., 2007).

Functions of YB-1
Transcription and Translation
As a transcription factor, YB-1 binds to the inverted CCAAT-box that is known as the Y-box in
the promoter regions of several eukaryotic genes involved in cell growth including proliferating
cell nuclear antigen (PCNA), epidermal growth factor receptor (EGFRα), DNA polymerase α
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and DNA topoisomerase II α (Wolfe, 1994; Ladometry and Somerville, 1995; Kohno et al.,
2003). In the cytoplasm, YB-1 acts as a RNA chaperone by associating with mRNAs to form
messenger ribonucleoprotein particles. YB-1 regulates translation in a dose-dependent manner;
low concentrations of YB-1 activate translation and high concentrations repress it (Evdokimova
and Ovchinnikov, 1999). YB-1 can shuttle to the nucleus and back to the cytoplasm, which
contributes to its function as a regulator of transcription and translation.

DNA Repair
YB-1 has been shown to be overexpressed in cisplastin-resistant cell lines and
reduction of YB-1 leads to increased sensitivity to cisplatin and other DNA interacting drugs
(Ohga et al., 1996). It is reported to interact with PCNA (Ise et al., 1999) and p53 (Okomoto et
al., 2000), which suggests that YB-1 may be involved in DNA repair and the DNA damage
response. Moreover, YB-1 is shown to possess 3’-5’ exonuclease activity (Izumi et al., 2001).
However, the regulation of this enzymatic activity in vivo is not known.

Drug resistance
The multidrug resistance gene (MDR-1) codes for P-glycoprotein (Pgp). Pgp is an ATP
binding cassette (ABC) transporter that is responsible for the efflux of a variety of compounds
out of the cell. These transporters act as a protective mechanism by reducing the toxins within a
cell but they can also cause drug resistance by eliminating clinically useful drugs. Nuclear
localization of YB-1 has been associated with the expression of Pgp and development of drug
resistance in breast cancer, melanoma and multiple myeloma (Janz et al., 2002; Schittek et al.,
2007; Chatterjee et al., 2007).
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Biological role of YB-1
YB-1 plays a role in embryonic development. Homozygous deletion of YB-1 in mouse
embryos results in late embryonic/perinatal lethality after embryonic day 13.5. This occurs due
to major developmental defects such as neurological abnormalities, hemorrhage and respiratory
failure. Moreover there is hypoplasia in multiple organ systems in late stage embryos that leads
to growth retardation. In this study, mice heterozygous for loss of YB-1 did not develop any
abnormalities in YB-1 function and were phenotypically indistinguishable from the wild type
littermates (Lu et al., 2005).

Figure 1.5. Model of YB-1 function. YB-1 is an important component of cellular stress
response pathway which protects cells from a variety of stresses. In mammalian cells, YB-1
expression is induced in response to environmental stress leading to its accumulation in the
nucleus. YB-1 deficiency results in the loss of this protective mechanism. Thus, cells deficient
in YB-1 show an increased sensitivity to environmental stresses and undergo premature
senescence.
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YB-1 is considered an important component of a cellular response pathway that is
required to protect cells from a variety of stresses (Figure 1.5). Fibroblasts derived from YB-1-/embryos demonstrated increased sensitivity to oxidative, genotoxic and oncogene induced stress.
Under oxidative stress, populations of YB-1-/- mouse embryonic fibroblasts have a large
percentage of cells in the G0/G1 phase of cell cycle. These cells accumulate negative cell cycle
regulators such as p16 and p21 and senescence prematurely (Lu et al., 2005). Two previous
studies reported that the loss of one functional allele of YB-1 resulted in a haplo-insufficient
phenotype in vitro. Targeted YB-1 heterozygous mutations in the chicken lymphoid DT40 cell
line showed major cellular defects such as aneuploidy and severe apoptosis (Swamynathan et al.,
2002). Targeted disruption of one allele of YB-1 in mouse embryonic stem cells caused
abnormal sensitivity to external cytotoxic stimuli (Shibhara et al., 2004). These studies suggest
that YB-1 plays a crucial role in cell growth and stress response.

Role of YB-1 in cancer
Similar to Hsp90, YB-1 has been shown to be overexpressed in variety of human
cancers including breast, thyroid, colorectal, prostate and melanoma (Kohno et al., 2003).
Several clinical studies revealed that increased YB-1 expression is associated with poor
prognosis in non small cell lung, prostate, ovarian and breast cancer (Kuwano et al., 2004). YB1 has been shown to play role in cell proliferation and cell cycle progression. Increased YB-1
expression is correlated with PCNA and DNA topoisomerase IIα expression in colorectal
cancer, human lung cancer and is linked to markers of cellular proliferation in osteosarcoma
(reviewed in Matsumoto and Bay, 2005). Further, YB-1 acts as a cell cycle stage-specific
transcription factor. In HeLa cells, nuclear accumulation of YB-1 transcriptionally activates
cyclin A and B1 genes, which are crucial for cell cycle progression (Jurchott et al., 2003).
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Figure 1.6. Schematic of the signal transduction pathways of YB-1 in cancer cells. Growth
factors such as insulin like growth factor, IGF-1, and cytokines activate various kinases that
can phosphorylate YB-1. It is generally thought that phosphorylation of YB-1 by kinases such
as Akt in the cytoplasm leads to nuclear trafficking and DNA binding. The phosphorylation of
YB-1 can also alter its role in translation initiation, mRNA splicing and/or transport. In the
nucleus, YB-1 directly binds to the inverted CAAT boxes and activates multiple genes involved
in cell growth. It can also indirectly induce the expression of oncogenes by binding to other
transcription factors such as AP-1 and p53. Thus, oncogene expression can be induced by YB-1
through transcriptional as well as translational control.
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In a transgenic mouse model, YB-1 has been shown to induce mammary tumor
formation through chromosomal instability. This chromosomal instability occurred due to
mitotic failure and centrosome amplification (Bergmann et al., 2005). In addition, YB-1 is
believed to promote tumor invasion and metastasis by controlling the expression of a matrix
metalloproteinase (MMP-2) (Cheng et al., 2002). Also, YB-1 has been reported to be involved
in inducing drug resistance in cancer cells. YB-1 positively regulates the transcription of
MDR1, and in a number of malignancies YB-1 levels are closely associated with the expression
of Pgp (Janz et al., 2002; Schittek et al., 2007; Chatterjee et al., 2007; Bargou et al., 1997).
Many proteins that phosphorylate YB-1 have an important role in the signal transduction
pathways associated with growth and survival of cancer (Figure 1.6). Various growth factors
such as insulin like growth factor (IGF-1) and cytokines activate kinases that can phosphorylate
YB-1. Phosphorylation by kinases such as Akt, MAPK, or Jak in the cytoplasm leads to the
nuclear translocation of YB-1 where it transactivates genes involved in cell growth (EGFR,
PCNA, Topoisomerase II α, DNA polymerase α), cell invasion (MMP-2) and represses genes
that induce apotosis (Fas) and cell differentiation (GM-CSF). Phosphorylation of YB-1 can also
alter its role in translation initiation, mRNA splicing and transport. In the nucleus, YB-1 directly
binds to inverted CAAT boxes and activates multiple genes involved in cell growth. It can also
indirectly induce the expression of oncogenes by binding to other transcription factors such as
activator protein (AP-1) and p53. Thus, oncogene expression can be induced by YB-1 through
transcriptional as well as translational control (Wu et al., 2007).
.
Role of YB-1 in hematological malignancies
Evidence for the involvement of YB-1 in hematological disorders such as MDS comes
from a gene array study where YB-1 expression was found to be higher in the bone marrow
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samples of MDS patients (Lee et al., 2001). A later study identified YB-1 as a gene that is
differentially expressed in the wild type and heterozygous GATA-1 knockdown mice. GATA-1
is a transcription factor essential for erythropoiesis, and heterozygous knockdown of GATA-1
in mice leads to maturation arrest and transformation of erythroblasts. GATA-1 knockdown
mice exhibit increased expression of YB-1 in its spleen as compared to wild-type mice
(Yokoyama et al., 2003a). GATA-1 mutant mice have a phenotype similar to humans with
MDS in early stages of life which transforms into acute leukemia in later stages of life. Another
study by the same group showed YB-1 mRNA to be highly expressed in the erythroblasts from
the patients with myelodysplastic syndrome refractory anemia (MDS-RA) relative to normal
patients (Yokoyama et al., 2003 b). These studies suggested a role for YB-1 in hematopoiesis,
particularly erythroid development. Recently, YB-1 was demonstrated to be strongly expressed
in immature and anaplastic multiple myeloma (MM) cells from the bone marrow of patients and
in various MM cell lines indicating its potential involvement in leukemia (Chatterjee et al.,
2007).
Though YB-1 has been studied extensively in solid tumors there is a paucity of
information about its role and regulation of gene expression in hematopoiesis. Also, there are
few studies demonstrating the association of YB-1 with MDS and leukemia. The objective of
the study in chapter 2 was to determine the role of YB-1 in hematopoiesis and leukemia. In
chapter 2, we show that YB-1 is highly expressed in stem/progenitor cells and is downregulated
during myeloid differentiation. Moreover, abnormal expression of YB-1 in leukemic cells could
contribute to their leukemic cell properties by blocking differentiation.
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Wnt signaling
In previous studies, it was shown that mutations in the chromatin remodeling genes or Hsp90 in
Drosophila resulted in the gain-of-function expression of Wg to produce an abnormal eye
phenotype. This phenotype was epigenetically inherited (Sollars et al., 2003). The studies
presented in chapter 3 were aimed to determine the effect of Hsp90 modulation on the Wnt
pathway in a mammalian model system.
Wnt signaling is involved in embryogenesis and controls diverse cellular behaviors
such as cell proliferation, stem cell maintenance and cell fate decisions. Dysregulated Wnt
signalling has been shown to be associated with cancer. Therefore, researchers have focused on
targeting this pathway for developing better therapies against cancer.
Investigators first identified Wnt genes independently in Drosophila and mouse.
Wingless (Wg) was identified as a segment polarity gene in Drosophila (Sharma and Chopra,
1976), while int-1 was cloned as a proto-oncogene in mouse (Nusse, 1984). The name “Wnt”
was derived from “wingless” and “int-1” after these two genes were shown to encode
homologous proteins (Rijsewijk et al., 1987).
In humans, there are at least 19 members of the Wnt family and at least 10 members of
its receptor family, FZ (frizzled) (Reya and Clevers, 2005; Mao et al., 2001). Wnt signals
transduce two distinct pathways: the canonical pathway for cell fate determination and the noncanonical pathway for the control of cell movement and tissue polarity. Canonical Wnts include
Wnt1, Wnt3A and Wnt 8 while non-canonical Wnts are Wnt4, Wnt5A and Wnt11.
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Figure 1.7. The canonical Wnt signaling pathway. (A) In the absence of Wnt binding to Fz,
Dsh remains unactivated and ß-catenin is bound by the destruction complex composed of APC/
Axin/ GSK-3β. This complex phosphorylates β-catenin and is targeted for degradation. (B)
When Wnt binds to Fz, Dsh is activated and uncouples β-catenin from the complex. β-catenin
can then associate with transcription factors and mediate transcription of the target gene.
Frizzled (Fz), Adenomatous polyposis coli (APC), dishevelled (Dsh), Glycogen synthase kinase
3β (GSK-3β), Lymphoid enhancer-binding factor (LEF), T-cell factor (TCF), Adenomatous
polyposis coli (APC).

The most studied Wnt pathway is the canonical pathway (Figure 1.7), which is
activated by the binding of a Wnt ligand to a frizzled receptor (Reya and Clevers, 2005). In the
absence of Wnt, ß-catenin is bound by the multiprotein “destruction complex” composed of the
tumor suppressors, APC (adenomatous polyposis coli) and Axin. These latter protein bind and
present ß-catenin to the kinases, glycogen synthase kinase 3 ß (GSK3 ß) and casein kinase I
(CKI). This results in phosphorylation of ß-catenin and thereby it is targeted for
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polyubiqitination and proteasomal degradation. In the presence of Wnt, ß-catenin binds to FZ
and inhibits the destruction complex so that ß-catenin remains unphosphorylated. This results in
the translocation and accumulation of ß-catenin in the nucleus. In the nucleus it interacts with
the TCF/LEF family of transcription factors to activate downstream target genes such as c-Myc,
CyclinD1 and matrix metalloproteinase (MMP) that regulate cell proliferation, differentiation
and survival (Mc Donald et al., 2006).
Canonical Wnt signaling is associated with the pathogenesis of several carcinomas.
Dysregulation of Wnt/ ß-catenin signaling is involved in the initiation of colorectal
carcinogenesis. APC is a tumor suppressor gene that can down-regulate the transcriptional
activation mediated by Wnt/ß-catenin. APC mutations result in its inactivation and
concominant loss of the inhibition of Wnt. Moreover, mutations of ß-catenin in the functionally
significant phosphorylation sites have been detected in colorectal cancer (Morin et al., 1997).
Furthermore mutations in members of the Wnt/ß-catenin pathway have been reported in
hepatocellular and gastric cancers (Polakis et al., 2000). Aberrant activation of the Wnt
canonical signaling pathway is involved in pathogenesis of many types of cancers, making this
pathway an attractive therapeutic target.

Wnt signaling and hematopoietic stem cells
The Wnt/ ß-catenin signaling pathway has been shown to have an effect on controlling
the proliferation, survival and differentiation of hematopoietic cells. It has been shown that
expansion of HSC occurs in long-term cultures due to the overexpression of activated ß-catenin.
These expanded HSCs retained the functional characteristics of HSCs and are able to
reconstitute the hematopoietic system in vivo (Reya et al., 2003).
Activation of Wnt signaling pathway has been implicated in the pathogenesis of various
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hematological malignancies including leukemia. ß-catenin activation coupled with GSK3 ß
inactivation has been demonstrated in precursor B-cell acute lymphoblastic leukemia (ALL).
The granulocyte macrophage progenitor (GMP) has been identified as a candidate leukemic
stem cell in blast crisis chronic myelogenous leukemia (CML), and it has elevated levels of
nuclear ß-catenin (Jamieson et al., 2004). Also, constitutive expression of active ß-catenin in
vivo has been shown to result in loss of myeloid lineage commitment at the GMP stage,
blocking erythrocyte differentiation and disrupting lymphoid development (Kirstetter et al.,
2006). Recently, it has been found that the Wnt/ ß-catenin signaling pathway is required for
self-renewal of leukemic stem cells (LSCs) that are derived from either HSC or more
differentiated GMP (Wang et al., 2010). This suggests the involvement of active ß-catenin in
leulemogenesis.
In the Drosophila model Wnt signaling was shown to be epigenetically regulated
(Sollars et al., 2003). Epigenetics involves changes in gene expression that are propagatable
through mitosis or meiosis, and are caused by mechanisms other than a change in the DNA
sequence. These can occur through DNA methylation, histone modifications, or non-coding
RNA. Secreted frizzled related proteins (SFRP), which act as Wnt antagonists, can inhibit WntFrizzled interaction by sequestration of the ligand. SFRPs have been shown to be regulated by
promoter hypermethylation and have been implicated in various cancers (Suzuki et al., 2004;
Fukui et al., 2005; Marsit et al., 2006). Recently, SFRPs have also been found to be
downregulated or inactivated by promoter hypermethylation in acute lymphocytic leukemia
(ALL) and AML (Jost et al., 2008).
Inhibition of Hsp90 in Drosophila resulted in the up-regulation of Wg to produce an
abnormal eye phenotype via epigenetically regulation (Sollars et al., 2003). In chapter 3 we
wanted to determine the effect of Hsp90 modulation on the Wnt pathway in a mammalian
model system. We obtained mixed results in this study since the in vitro model system does not
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recapitulate the stem cell niche seen in vivo. Hsp90 interacts with numerous signal transduction
proteins including chromatin remodeling complexes. Therefore, there is a possibility that Hsp90
has an effect on the Wnt pathway, and if this can be demonstrated it will have profound
implications for the treatment of cancer as Wnt signaling is activated in various cancers.

Omega Fatty acids and cancer
In recent years, there has been increased focus on the role of specific dietary fatty acids
and their effect on health and disease. Researchers have been studying the effects of poly
unsaturated acids (PUFA) on cancer. This interaction will be important in devising new
therapies for treatment and chemoprevention against cancer. AML is characterized by the
inhibition of myeloid progenitor cell differentiation. Omega fatty acids have been shown to
promote myeloid differentiation. Moreover, Wnt signaling has been demonstrated to be active
in AML. Therefore, in the studies described in chapter 4 we have investigated the effect of
omega fatty acids on Wnt signaling in the hematopoietic system.
Fatty acids (FA) are carboxylic acids with long hydrocarbon chains that can be
saturated or unsaturated depending upon the presence of double bonds in the carbon chain.
Fatty acids with multiple sites of unsaturation are termed as PUFAs. Omega-6 FAs are derived
from linoleic acid (LA, 18:2) and the omega-3 FA are derived from α-linolenic acid (ALA,
18:3). LA is metabolized to arachidonic acid (AA, 20:4, omega-6), while ALA can be
metabolized to eicosapentaenoic acid (EPA, 20:5, omega-3) and ultimately docosahexanoic
acid (DHA, 22:6) (Anderson and Ma, 2009). Linoleic acid and α-linolenic acid are omega-3
and omega-6 PUFAs that are essential for survival and must be obtained from dietary source,
since they cannot be synthesized in mammals. Omega-3 (EPA) and Omega-6 (AA) PUFA are
classified depending on the location of the first double bond relative to the methyl terminus
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(Das, 2008) (Figure 1.8).

Figure 1.8. Omega-3 and omega-6 Polyunsaturated fatty acids (PUFA). (A) Arachidonic
acid with first double bond at carbon 6 from the methyl terminus. (B) Eicosapentanoic acid with
first double bond at carbon 3 from the methyl terminus.

Omega-6 and omega-3 FA are important structural components of the phospholipid cell
membranes and are essential for the activity of membrane-bound enzymes and receptors as well
as signal transduction. Polyunsaturated FAs are substrates for eicosanoid synthesis, with omega-6
FAs converted into pro-inflammatory eicosanoids and omega-3 FAs being converted into antiinflammatory eicosanoids. High omega-6/omega-3 tissue ratios contribute to the development of
chronic diseases in later life such as coronary heart disease and stroke, or diabetes (Institute of
medicine, 2005). Several studies suggest that omega-6 FA promote cancer development
(Williams et al., 2011) while omega-3 FA suppresses tumor carcinogenesis (Augustsson et al.,
2003; DeDecker, 1999; Calviello et al., 2009).
Omega fatty acids have been found to have effects on the hematopoieis. Eicosanoids
derived from AA metabolism (omega-6 FA) have been shown to play a role in myelopoiesis
and erythropoiesis (Dupuis et al., 1997). High omega-3/omega-6 FA ratio in the diet has been
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reported to promote differentiation and reduce the frequency of myeloid progenitor cells in the
bone marrow of mice (Varney et al., 2009). Abnormal hematopoiesis results in excessive
proliferation of immature blasts and inhibition of their differentiation into mature blood cells.
This can lead to myeloproliferative disorders and leukemia. Since omega-3 FAs have been
shown to promote differentiation they can be used as a therapeutic approach in leukemia.
Wnt signaling plays an important role in hematopoietic self renewal and differentiation
(Reya et al., 2003). Prostaglandin (PGE2) derived from AA (Omega-6 FA) metabolism
regulates vertebrate HSC induction and engraftment (North et al., 2007). Recently, it was
reported that PGE2 interacts with Wnt and together they regulate murine stem and progenitor
populations in vitro and in vivo (Goeslling et al., 2009). Inhibition of PGE2 synthesis blocked
Wnt-induced alterations in HSC formation at the level of ß-catenin. This suggests that omega-6
FAs might play role in promoting HSC proliferation.
Aberrant Wnt signaling is associated with different cancers including AML and CML
(Jamieson et al., 2004). Earlier studies with Drsophila demonstrated the up-regulation of Wnt
signaling after inhibition of Hsp90 by an epigenetic mechanism. SFRP which act as Wnt
antagonists can inhibit Wnt-frizzled interaction by sequestration of the ligand. SFRP are
negatively regulated by epigenetics (DNA methylation) and this leads to up-regulation of Wnt
signaling. Up-regulation of Wnt signaling through down-regulation of SFRP occurs in ALL and
AML (Jost et al., 2008). Recently investigators reported that omega-3 fatty acids inhibited Wnt
signaling in hepatocellular and cholangiocarcinoma (Lim et al., 2008; Lim et al., 2009). This
suggests that omega-3 FA may be involved in the inhibition of Wnt signaling in leukemia by
the down-regulation of SFRP.
Since Wnt signaling is important in hematopoietic stem cell maintenance and is
involved in leukemia, I hypothesized that omega-3 FA might induce differentiation in leukemic
cells by inhibiting the Wnt signaling via an epigenetic mechanism. To investigate the effects of
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omega-3 and omega-6 FAs on the Wnt pathway I used a stem cell model, EML cells and
leukemic cells. Wnt signaling activity was examined based upon the accumulation of ß-catenin
in the nucleus. In chapter 4, our prelimiary data initially showed that Wnt signaling is downregulated upon exposure to omega-3 FAs in EML cells as well as HL-60 leukemic cells.
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Abstract
Hematopoietic transcription factors play a critical role in directing the commitment and
differentiation of hematopoietic stem cells along a particular lineage. Y box protein (YB-1) is a
transcription factor which is widely expressed throughout development and is involved in
erythroid cell development, however its role in early hematopoietic differentiation is not
known. Our objective was to investigate the role of YB-1 expression in early hematopoietic
differentiation and leukemia. Here, we show that YB-1 is highly expressed in mouse erythroid,
myeloid lymphoid-clone1 (EML), a hematopoietic precursor cell line, but is downregulated in
myeloid progenitors, and GM-CSF treated EML cells. Moreover, we found that lineage−/IL7R−/c-kit+/Sca1+ (LKS; enriched fraction of hematopoietic stem cells) and lineage−/IL-7R−/ckit+/Sca1− myeloid progenitor cells showed a high level of YB-1 expression as compared to the
differentiated cells like granulocytes in mouse bone marrow (BM). Also, YB-1 protein was
expressed at high levels in myeloid leukemic cell lines blocked at different stages of myeloid
development. We further investigated the role of YB-1 in leukemic cells by knockdown studies
and observed that down-regulation of YB-1 expression in K562 leukemic cells inhibited their
proliferation ability, induced apoptosis and differentiation towards megakaryocytic lineage.
Overall, our data indicates that YB-1 is down-regulated during myeloid differentiation and the
aberrant YB-1 expression in leukemic cells could be a contributing factor in the development of
leukemia by blocking their differentiation. Thus, YB-1 protein could be an excellent molecular
target for therapy in myeloproliferative disorders and leukemia.

Key words: YB-1, EML cells, K562 cells, differentiation, mouse stem and progenitor cells
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Introduction
Hematopoiesis is the process by which all the different cell lineages that form the blood
and immune system are generated from a common pluripotent stem cell. It is maintained by a
proper balance between self renewal and multi-potent differentiation of the hematopoietic stem
cells (HSC) (Huntley and Gilliland., 2005). Transcription factors play a major role in
differentiation in a number of cell types, including the various hematopoietic lineages (Tenen et
al., 1997). Among the best examples are PU.1, CCAT/enhancer binding protein α (C/EBPα),
AML1, Globin Transcription Factor (GATA-1), c-myb, and SCL/Tal1 (Rosenbauer et al.,
2005). Myeloid gene expression is controlled by the combinatorial effects of several key
transcription factors. Alteration of myeloid transcription factors (changes in expression and
structure) lead to abnormal myelopoiesis and dysplasia (Tenen et al., 1997). Consequently, a
major focus of research in this area has been on the molecular mechanism controlling normal
myeloid differentiation. To better understand the process of normal hematopoietic
differentiation, it is important to identify and characterize the differential expression of
transcription factors in HSCs and terminally differentiated cells.
It is difficult to study the early stages of hematopoietic differentiation because few
experimental models are available to approach this question. The Erythroid Myeloid Lymphoidclone 1 (EML) cell line, developed from murine bone marrow cells transfected with a vector
expressing a dominant negative form of the retinoic acid receptor, provides a unique in vitro
model to address this question. EML cells can be indefinitely propagated in medium containing
stem cell factor (SCF) and can be differentiated into erythroid, myeloid, lymphoid lineages by
the addition of appropriate cytokines (Tsai et al., 1994).
The Y-box protein (YB-1), also known as p50 or dbpB belongs to a superfamily of cold
shock proteins that are highly conserved during evolution (Toh et al., 1998). Y-box protein is
involved in a wide variety of cellular functions, such as regulation of DNA transcription and
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translation (Evdokimova et al., 2006). YB-1 null mice can survive organogenesis and the
majority of homozygous null embryos survive to day 18.5 of gestation (Lu et al., 2005).YB-1 is
an integral part of the cellular stress response signaling pathway required for protecting cells from
a variety of stresses and prevention of premature senescence in cultured primary cells (Lu et al.,
2005). Y-box elements are present in the promoters of several genes associated with cell division,
therefore it is suspected that YB-1 has a role in promoting cell proliferation (Wolfe 1994;
Ladomery and Sommerville 1995). It has also been shown that down-regulation of YB-1 results
in reduced proliferation and increased apoptotic cell death rates in multiple myeloma cells
(Chatterjee et al., 2008). The YB-1 transcript and protein have also been detected in mouse
embryonic stem cells (Shibahara et al., 2004). In summary, there is evidence for YB-1 having a
role in cell proliferation, cell survival and protecting against apoptosis.
Increased nuclear and cytoplasmic expression of YB-1 has frequently been detected in
a wide range of human cancers, including breast, thyroid, colorectal, osteosarcomas, and
synovial sarcomas (Kohno et al., 2003). Clinical studies on YB-1 have shown close association
of the cellular level of YB-1 with tumor growth and prognosis in ovarian, lung and breast
cancers (Kuwano et al., 2004). YB-1 controls the expression of genes involved in tumor
progression including matrix metalloproteinase-2 (MMP-2) and the multidrug resistance gene 1
(MDR-1) (Mertens et al., 1997; Ohga et al., 1998). Enhanced YB-1 expression is associated
with tumor progression and drug resistance in melanoma and multiple myeloma (Schittek et al.,
2007; Chatterjee et al., 2008).
Knockdown of GATA-1, a transcription factor essential for erythropoiesis in mice,
leads to maturation arrest and transformation of erythroblasts. The GATA-1 mutant mouse
(knockdown mouse) exhibits increased expression of YB-1 in its spleen as compared to the
wild type mouse (Yokoyama et al 2003 a, b). Moreover, expression of YB-1 was found to be
higher in the bone marrow samples of MDS patients (Lee et al., 2001). The expression of YB-1
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is higher in erythroblasts in myelodysplastic syndrome-refractory anemia (MDS-RA) than in
normal cells suggesting a role of YB-1 in erythropoiesis (Yokoyama et al., 2003 a, b).
Since the role of YB-1 in normal hematopoietic differentiation has not been elucidated,
we examined the expression of YB-1 in the mouse hematopoietic EML cell line and in vivo
during myelopoiesis. To further investigate its possible role in leukemogenesis, we have
determined the expression and function of YB-1 protein in human leukemic cells.

Materials and Methods
Cell Culture
EML C1 cells were the kind gift of Dr. Schickwann Tsai and were maintained in
Iscove’s modified Dulbecco medium (IMDM,) supplemented with 20% horse serum (American
Type culture collection, ATCC, Manassas, VA) and 10% BHK/MKL-conditioned medium
(Tsai et al., 1994). For differentiation studies, EML cells were induced to differentiate into
myeloid cells with 10 µM all-trans retinoic acid (ATRA (RA); Sigma, St. Louis, MO, USA),
10% BHK conditioned medium (source of stem cell factor) and 15% WEHI conditioned
medium (source of interleukin-3) for three days. Cells were then cultured again in IMDM/20%
horse serum with 20 ng/ml of murine granulocyte-monocyte colony stimulating factor (GMCSF) (Stem cell tech. Vancouver, BC, Canada) for the next three days. HL-60 (human
promyelocytic leukemia), K-562 (human myelogenous leukemia) (Lozzio and Lozzio 1975); U937 (human promonocytic leukemia), WEHI-3 (murine monocytic leukemia) cells were
purchased from the ATCC and cultured according to their guidelines.
Mouse strains
C57BL/6J mice were bred and maintained at the AAALAC accredited animal care
facility at Marshall University in accordance with the university guidelines. Donor mice used
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for bone marrow isolation were 8-10 months of age. Mice were sacrificed for these experiments
according to institutional guidelines.
Flow cytometry studies
Stable clones with YB-1 shRNA in K562 cells: Sh6-, Sh7-, Sh8- were seeded at a density
of 1x105 cells/ml in a six-well plate and treated with 0.5µM As2O3 for 72 hours. Treated as well as
untreated EML and K562 cells were washed twice with FACS buffer (Phosphate buffered saline,
PBS supplemented with 3% BSA, 0.02% sodium azide and 1mM EDTA) and collected by
centrifugation. Thereafter they were incubated with FcγRII/III antibody (553142, BD
Pharmingen) to prevent nonspecific binding by blocking the Fc receptors for half an hour at 4°C.
For EML cells the cells were washed again and labeled with PE conjugated anti-Sca-1 (clone D7,
553108), PE conjugated anti-c-Kit (clone 2B8, 553355), biotinylated anti-CD11b (clone M1/70,
553309, BD Biosciences) or PE conjugated anti-F4/80 (clone BM8, MF48004, Caltag) for 30
minutes on ice. After washing the EML cells biotinylated anti-CD11b antibody was labeled with
strepavidin APC (SA1005, Molecular probes). K562 cells were washed and labeled with APC
conjugated mouse anti-human CD41a antibody (clone HIP8, 559777, BD biosciences) for 30
minutes on ice. Data acquisition was performed using BD FACS Aria sorter and data analysis
was done using Flow Jo software v.7.5.5 (Treestar, Ashland, OR).

Cell staining and sorting
Bone marrow (BM) was harvested from C57BL/6J donor mice by flushing both femur
and tibia with PBS/2% FBS. Heart punctures were performed to isolate serum from the mice.
Cells were washed with 1X PBS by centrifugation and resuspended in PBS/2%FBS buffer
followed by the addition of 10% mouse serum at 4°C for half an hour to block the Fc receptors to
prevent any nonspecific binding. For isolation of HSC and progenitor cells, 2.5X107 bone
marrow cells were incubated for half an hour on ice with 100 µl of each of the following
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biotinylated lineage specific antibodies to identify terminally differentiated cell types: CD3e
(clone 145-2C11), CD11b (clone M1/70), B220 (clone RA3-6B2), Gr-1 (clone RB6-8C5), TER119 (anti-erythrocyte specific antigen), IL-7Rα chain (clone B12-1) (Lineage panel; 559971,
Becton Dickenson-Pharmingen). Cells were labeled with PECy7 conjugated anti-Sca-1 (clone
D7, 25-5981) and APCCy7 conjugated anti-c-Kit (clone 2B8, 25-1171; eBioscience, San Diego,
CA) monoclonal antibodies. After washing with PBS/2% FBS the cell suspension was incubated
with strepavidin pacific blue conjugate (Molecular probes, Invitrogen) for 30 minutes on ice.
Murine hematopoietic stem cells (lineage−/IL-7R−/c-kit+/Sca1+) and myeloid progenitors
(lineage−/IL-7R−/c-kit+/Sca1−) were sorted from bone marrow, as described previously (Akashi et
al., 2000). For the isolation of granulocytes, bone marrow cells were stained with biotinylated Gr1 and visualized by a strepavidin pacific blue conjugate. All cell populations were sorted using
BD FACS Aria multicolor cell sorter and data analysis was done using DIVA and Flow Jo
software (Treestar, Ashland, OR). A second round of sorting was performed to ensure pure
populations. RNA was isolated from multiple independently isolated samples containing normal
HSC, myeloid progenitors and granulocytes.

RNA extraction and quantitative RT-PCR
RNA was isolated from double sorted HSC & progenitor cells obtained from mouse bone
marrow or from EML cells using an RNeasy kit according to the manufacturer’s instructions
(Qiagen, Valencia, CA). cDNA was synthesized by using the Advantage RT-for-PCR kit®
according to the manufacturer’s guidelines (Clontech, Mountain View, CA). Gene expression
analysis designed against mouse YB-1 (catalog no. ABI Mm00850878) was performed using
TaqMan Gene Expression Assays on an ABI Prism 7000 sequence detection system (Applied
Biosystems, Foster City, California, USA). Expression of the β-actin gene (catalog no. ABI,
4352341E) was used to normalize the amount of the investigated transcript. Data were corrected
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for efficiency and loading using the Pfaffel method (Tichopad et al., 2003). Data shown are
representative of four independent experiments.
Western blotting
Treated cells from different experimental conditions were rinsed once with ice-cold PBS
and then separated into nuclear and cytoplasmic fractions using the NE-PER extraction kit as per
the manufacturer’s instructions (Pierce, Rockford, IL). Protein concentration was determined
using bicinchoninic acid (BCA) protein assay reagents from Pierce according to the
manufacturer’s guidelines. Cell extracts were then denatured at 95°C for 5 min in 2x sample
buffer (62.5 mM Tris HCl (pH 6.8), 25% glycerol, 0.01% bromophenol blue, 2% SDS, 10% βmercaptoethanol). Equal amount of protein extracts were separated on an 8-16% gradient TrisGlycine SDS–poly acrylamide gel (Bio-Rad, Hercules, CA) by electrophoresis (PAGE) and
transferred onto nitrocellulose membranes (Millipore) using the Bio-Rad MiniProtean3® system.
The membranes were treated in blocking solution (5% non fat dry milk in TBS containing 0.1%
Tween 20) and incubated with primary YB-1 rabbit polyclonal antibody (1µg/ml, 2749, Cell
Signaling Technologies, Danvers, MA) overnight at 4°C, followed by incubation with HRPconjugated monoclonal rabbit secondary IgG antibody (1: 3000, 7074, Cell Signaling). An antimouse GAPDH antibody (MAB374, GE Healthcare, CT) was used to assess equal loading.
Proteins were visualized by enhanced chemiluminescence (ECL) (GE Healthcare, CT).
Benchmark TM protein ladder was used to visualize the transfer of protein onto the membrane and
MagicMark TM XP (Invitrogen) was used as a molecular size standard.

Wright-Giemsa staining
EML cells at different stages of myeloid cell differentiation were cytospun onto
microscopic slides and stained with Wright-Giemsa stain (Accustain, sigma) and light
microscopy images (400x) taken using an Olympus BX51 system microscope attached to a DP70
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microscope digital camera. Captured images were analyzed for morphological changes during
myeloid differentiation with DP70 software on a Dell optiplex GX280 computer.

Transfection of leukemia cells and generation of stable clones
The shRNA expression vector for YB-1 (YB-1-pSUPER with the target sequence
GAAGGTCATCGCAACGAAG, shYB-1) for generating YB-1 specific shRNAs and control
shRNAs has been described previously (Schittek et al., 2007; Huber et al., 2004). This vector
does not have a selectable marker. To generate stable clones, K562 leukemia cells (Lozzio CB,
Lozzio BB, 1975) were cotransfected with the YB-1 pSUPER vector and for neomycin
selection ; pEGFPN3 vector (Clontech, Saint-Germainen- Laye, France) by electroporation
using BTX electroporation system as per manufacturer’s instructions (Genetronics, San Diego,
CA). K562 cells or pEGFP transfected K562 leukemia (Empty vector, EV) cells served as
controls. K562 cells were selected with 800 µg/ml G418, 48 hrs after transfection, for 2 weeks,
thereafter GFP +ve cells were sorted and recultured in G418 media for another 2 weeks. When
stable clones were generated the G418 dose was reduced to half. Three stable clones sh6-, sh7and sh8- from the YB-1sh/EGFP were confirmed for YB-1 knockdown by western blotting and
were further analyzed.
Cell Viability Assay
Stable clones with YB-1 shRNA in K562 cells: Sh6-, Sh7-, Sh8- were treated with 0.5
µM As2O3 (Alfa Aesar, Massachusetts, USA) and cell viability assay was performed at 24, 48,
72 hours using the trypan blue dye exclusion method.
Apoptosis assay
Stable clones with YB-1 shRNA in K562 cells: Sh6-, Sh7-, Sh8- were seeded at a
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density of 1x105 cells/ml in a six-well plate and treated with 0.5 µM As2O3 for 72 hours. The
cells were harvested and washed with cold PBS and resuspended in the binding buffer (100 µl
of calcium buffer containing 10 mM HEPES/NaOH, ph7.4, 140 mM NaCl, 2.5 mM CaCl2)
containing 5 µl annexin V-pacific blue and 5 µl 7 AAD (5 µg/ml). The samples were incubated
for 30 minutes in the dark at room temperature and then subjected to flow cytometry.
Morphological evaluation of differentiated cells
Stable clones with YB-1 shRNA in K562 cells: Sh6-, Sh7-, Sh8- were treated with
0.5µM As2O3 for 72 hours and cell morphology was determined by examining light microscopy
images (400x) taken using an Olympus BX51 system microscope.
Cell cycle analysis by flow cytometry
Stable clones with YB-1 shRNA in K562 cells: Sh6-, Sh7-, Sh8- were seeded at a
density of 1x105 cells/ml in a six-well plate and treated with 0.5µM As2O3 for 72 hours. Cells
were harvested and washed twice with PBS, fixed in 70% ethanol overnight at 4°C. Cells were
then stained with 5 µl (1 mg/ml) propidium iodide (PI) containing 2.5 µl (10 mg/ml) RNase for
30 minutes at 37°C and analyzed by flow cytometry on an Accuri C6 flow cytometer.
Statistics
Statistical analysis of the data was performed using the Student t test or ANOVA
followed by a Student t test with corrections for multiple comparisons using the Bonferroni
method as appropriate. The statistical test used for each data set is stated in figure legends; p <
0.05 was considered to be significant. Data are presented as means plus or minus standard error of
mean (SEM).
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Results
EML cells as a model of myeloid differentiation
The EML cell line is a SCF dependent multipotent cell line with myeloid, erythroid and
lymphoid potentials. It was established from mouse bone marrow infected with a retroviral
vector (LRARα403SN) harboring a dominant negative retinoic acid receptor (RAR construct)
(Tsai et al., 1994).

Figure 2.1. Morphology of EML cells during RA and GM-CSF induced differentiation.
Cytospin preparations of the indicated cells were stained with Wright-Giemsa. (A) Native
DMSO treated SCF dependent EML cells. Arrows indicate hand-mirror-shaped cells that are
frequently seen in EML cell line. (B) EML cells treated with SCF/IL-3 and 10 µM RA for three
days. Arrows show the granulocyte-monocyte progenitors (CFU-GM) indicated by the increase
in nuclear to cytoplasmic ratio. (C) EML/RA+IL-3 cells treated with GM-CSF for another three
days. Magnification is 400x. Arrows show the committed granulocytic/monocytic progenitors
with bi-lobed nucleus. Scale bars are 50 µm.
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It is a suspension cell line consisting of mostly blast like cells with 20-30% hand mirror shaped
cells (Figure 2.1A).

EML cells serve as an excellent model to study hematopoietic

differentiation in vitro (Johnson et al., 1999).

It can be induced to differentiate towards

granulocyte/monocyte progenitors (CFU-GM) by high concentration of RA in the presence of
IL-3 (Figure 2.1B).

These CFU-GMs can be further differentiated into more committed

granulocyte/monocyte progenitors by GM-CSF treatment (Figure 2.1C).
To characterize the differentiation pattern of EML cells with our cytokine treatments,
we analyzed cell markers associated with several stages of differentiation. We compared the
cell surface marker profile of native, DMSO-treated EML cells, EML cells treated with RA+IL3 (CFU-GM) for three days, and EML cells treated for an additional 3 days with GM-CSF after
the RA+IL-3 treatment. Flow cytometry analysis was performed using the following panel of
antibodies: (1) anti-Sca-1, which is specific for stem cells, (2) anti-c-kit specific for
stem/progenitors, (3) anti-CD-11b specific for macrophage/neutrophil lineages, and (4) antiF4/80 specific for macrophages (Figure 2.2). The parental EML cells appear relatively undifferentiated (Figure 2.2A) and display an immature surface antigen phenotype that is
characterized by high Sca-1+ and c-kit+ (Figure 2.2 A, B) expression and absence of CD11b
and F4/80 (Figure 2.2 C, D). In contrast, the EML/GM-CSF cells appear more differentiated
(Figure 2.2 C) and display cell surface markers indicative of differentiated cells (CD11b+,
F4/80+) with a loss of stem/progenitor markers such as Sca-1 and c-kit. Sca-1 expression in
GMCSF treated EML cells was >90% reduced (p<0.01) while CD11b (p<0.01) and F4/80
(p<0.01) showed >95% & 59% increase respectively as compared to the untreated EML cells
(Figure 2.2 E). This data indicates that EML cells express stem and primitive progenitor
markers. When these cells are subjected to conditions that induced myeloid progenitors (CFUGM), there is an increase in the expression of granulocyte/monocyte specific markers, which
becomes more predominant with the appearance of more committed granulocyte/monocyte
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progenitors.

Figure 2.2. Cell surface marker profile of Untreated, RA and GM-CSF treated EML cells.
EML cells were induced to undergo myeloid differentiation in the presence of SCF, IL-3 and
RA for three days followed by GM-CSF for three days as described in materials and methods.
Samples were collected at day 3 and day 6 for RA & GM-CSF treated EML cells respectively.
Expression of (A) Sca-1, (B) c-kit which label primitive stem/progenitor cell types and (C)
CD11b, (D) F4/80 specific for granulocytes and macrophages in DMSO treated (black line),
RA (grey dashed line) and GM-CSF ( solid grey line) treated EML cells. (E) Combined flow
cytometric analysis of DMSO treated, RA+IL-3, and GM-CSF treated EML cells in terms of %
positive cells for each surface antigen. Data is expressed as the mean ± SEM of triplicate
values. Analysis of variance (ANOVA) for multiple pairwise comparisons was used to analyze
the data along with Student t test comparing each to untreated EML cells. (* indicate p≤ 0.01).
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YB-1 expression in undifferentiated vs. differentiated EML cells
YB-1 functions in erythroid differentiation and aberrant expression of YB-1 leads to
abnormal erythropoiesis but its role and regulation of gene expression in early hematopoiesis is
still unknown (Yokoyama et al., 2003). In order to characterize its pattern of expression in early
hematopoiesis, YB-1 protein expression was studied by western blot analysis in DMSO-treated,
RA+ interleukin-3 (IL-3) treated and GM-CSF treated EML cells (Figure 2.3). YB-1 was detected
as 49 kD protein in nuclear extracts. YB-1 protein was highly expressed in native EML cells
relative to RA+IL-3 and GM-CSF treated cells (Figure 2.3A, B). RA+IL-3 treated EML cells
(myeloid progenitors) showed a significant decrease (>60%; p<0.05) in YB-1 protein expression
compared to the DMSO treated EML cells. This reduction was even more apparent in the GMCSF treated (>80%; p<0.05) compared to the DMSO treated EML cells.
In order to determine if YB-1 protein levels correlate with the mRNA, we analyzed YB-1
mRNA expression in the above three cell populations by quantitative RT-PCR (Figure 2.3 C).
YB-1 mRNA levels were down-regulated in RA+IL-3 treated relative to the DMSO treated EML
cells and reduced further significantly with GM-CSF treatment (p<0.05). These data show that
YB-1 mRNA and protein expression pattern correlate and are highly expressed in native
undifferentiated EML cells but both levels are dramatically down-regulated during EML cell
differentiation. Taken together, this data indicates that YB-1 is expressed in undifferentiated stem
cells and reduces as these cells progress into early and later stage progenitors. The functional role
of YB-1 expression is not known.
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Figure 2.3. Expression of YB-1 mRNA and protein in EML cells. (A) Nuclear extracts from
DMSO treated, RA and GM-CSF treated EML cells were subjected to SDS- PAGE and western
blot analysis with an anti-YB-1 antibody (1µg/ml). GAPDH was used as a loading control. (B)
SEM of values obtained from densitometric analysis of three individual
The mean
experiments. ANOVA for multiple pairwise comparisons was used to analyze the data along
with Student’s t-test comparing each to untreated EML cells (* indicate p< 0.05). This blot is
representative of at least 3 different experiments, all of which gave similar results (N=9). (C)
Total RNA was extracted from untreated, RA and GM-CSF treated EML cells by RNeasy kit
and was reverse transcribed using Advantage RT-for-PCR kit®. Real-Time PCR analysis was
performed using TaqMan probes directed at YB-1 and β-actin. Data was analyzed with
ANOVA and is expressed as fold change, corrected for β-actin, relative to untreated EML cells
(* indicate p< 0.05). Data is representative of experiments (N=6).
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Expression of YB-1 in mouse stem and progenitor cells
Though the EML cell culture system has proved useful in identifying changes in YB-1
gene expression during hematopoietic differentiation, it is an immortalized cell line and thus
may not accurately represent normal hematopoietic cells (Ye et al., 2005). To compare changes
in YB-1 gene expression observed in EML cells with normal hematopoiesis, we sorted stem
cells, myeloid progenitors, and granulocytes from C57BL/6 mouse BM. In mice, multipotent
hematopoietic activity resides in a small fraction of BM cells lacking the expression of lineageassociated surface markers but expressing high levels of Sca-1 and c-Kit (LKS fraction).
Within the lineage− BM cells myeloid progenitors can be isolated from the IL-7Rα− fraction by
the absence of Sca-1 expression, but the presence of c-Kit . Based on Sca-1 and c-kit profile of
lineage−/IL-7R−bone marrow cells, a population enriched in HSC was sorted according to
lineage−/IL-7R−/c-kit+/Sca1+ (LKS) marker profile while myeloid progenitors were separated
based on lineage−/IL-7R−/c-kit+/Sca1− profile (Figure 2.4A-C). Granulocytes were isolated
from mouse BM by staining with anti Gr-1 antibody as shown in Figure 2.4D and E. In these
three populations, YB-1 mRNA levels were measured by quantitative RT-PCR (Figure 2.4F).
There was a significant two-fold increase in YB-1 mRNA levels in myeloid progenitors
(p<0.05) as compared to the LKS fraction (enriched fraction for stem cells). More noteworthy
is the statistically significant reduction in YB-1 mRNA levels in granulocytes which is reduced
by more than 87% as compared to the stem/progenitor cells (p<0.01). These data indicate that
YB-1 transcripts are highly expressed in stem/myeloid progenitors and down-regulated in more
differentiated cell types like granulocytes. These results are consistent with the in vitro data,
reinforcing the validity of the EML cell model and suggesting an in vivo role for YB-1 in
hematopoietic stem and progenitor cells.
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Figure 2.4. Expression of YB-1 in mouse stem and progenitor cells. (A) BM cells from adult
mice were isolated by flow cytometry. Cells of the appropriate side scatter and forward scatter
properties (R1) gate were further fractionated by (B) IL-7Rα and lineage panel depletion
represented by gate R2. (C) Those remaining were selected based upon c-kit and Sca-1
expression as indicated. The lineage−/IL-7R−/c-kit+/Sca1+ (LKS, enriched fraction for stem cells)
shown as R4 and lineage−/IL-7R−/c-kit+/Sca1− (myeloid progenitors, R3) fractions were then
sorted for quantitative RT-PCR. (D-E) Granulocytes were sorted from the mouse BM by
forward/side scatter characteristics (S1) and labeling with anti-Gr-1 antibody (S2). (F) Total
RNA was extracted from lineage−/IL-7R−/c-kit+/Sca1+ (LKS), lineage−/IL-7R−/c-kit+/Sca1−
(myeloid progenitors), and Gr-1+ populations followed by real-time RT-PCR was performed
using TaqMan probes directed at YB-1 and β-actin. The relative amount of mRNA in each cell
population was normalized to an internal control gene β-actin and expressed as fold change
relative to stem cells. The statistical significance of YB-1 expression was assessed by ANOVA
combined with the student's t-test (* indicate comparisons to stem cell levels, ^ indicate
comparisons to progenitor cell levels, p≤ 0.01). Data is representative of four independent
experiments (N=12).
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YB-1 expression in leukemic cells
YB-1 is involved in erythropoiesis and aberrant YB-1 expression may lead to
abnormalities in erythroid differentiation (Yokoyama et al., 2003). MDS is characterized by
ineffective production of mature blood cells due to increased proliferation and reduced
differentiation of hematopoietic stem/progenitor cells, with a high predisposition to transform
into acute leukemia (Greenberg et al., 1997).

Figure 2.5. YB-1 expression in leukemia (A) Western blot analysis was performed on the
nuclear extracts from HL-60 (human promyelocytic leukemia), U-937 (human promonocytic
leukemia), K-562 (human chronic myelogenous leukemia), WEHI-3 (murine monocytic
leukemia) cell lines using anti YB-1 antibody. Untreated, RA and GMCSF treated EML cells
served as positive and negative controls. GAPDH was used as a loading control. (B)
Densitometric analysis of the above western blot. This data is one representative of three
independent experiments all giving similar results.

YB-1 has been shown to be up-regulated in the bone marrow of patients with MDS
(Lee et al., 2001; Yokoyama et al., 2003). Since we saw a high expression of YB-1 in
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stem/progenitor cells as compared to differentiated cells, we investigated whether higher
expression of YB-1 is associated with leukemia. For this we performed western blot analysis
on protein extracted from several human and mouse leukemic cell lines (Fig. 2.5 A, B). DMSO
treated, RA+IL-3, and GMCSF treated EML cells served as references for these experiments.
HL-60 (human promyelocytic leukemia), U-937 (human promonocytic leukemia), K-562
(human chronic myelogenous leukemia), WEHI-3 (murine monocytic leukemia) cell lines
arrested at progenitor stage of myeloid differentiation expressed YB-1 at different levels. As
native EML cells are more like stem/early progenitor cells, they express high levels of YB-1
protein as compared to the more committed myeloid progenitors. YB-1 expression levels in all
the leukemic cell lines lie between stem and early myeloid progenitor state except the K-562
cell line, in which the expression is even higher than the EML cells. This data indicates that
YB-1 is highly expressed in myelogenous leukemias.

Biological significance of down-regulation of YB-1 expression on cell proliferation
apoptosis and differentiation in K562 leukemic cells
To determine the role of YB-1 in leukemic cells, we downregulated YB-1 in K562 cell
line (Lozzio and Lozzio, 1975), using specific shRNA and studied the effects of low YB-1
levels on cell proliferation and apoptosis. Three stable clones sh6-, sh7-, sh8- were selected and
down-regulation of YB-1 was confirmed by western blotting. Approximately a 40% reduction
in YB-1 expression was achieved compared to EGFP transfected K562 cells, empty vector (EV)
(Figure 2.6A).YB-1 down-regulation itself resulted in reduction in cell viability in sh6-, sh7-,
and sh8- K562 relative to the normal K562 cells and EV at 72 hours. There was a statistically
significant reduction in cell proliferation in sh6- (68%), sh7- (66%) & sh8- (66%) after
treatment with 0.5 µM As2O3 relative to the untreated K562 cells (p<0.01) (Figure 2.6B).

50

Figure 2.6. Effects of down-regulation of YB-1 expression on cell proliferation and
apoptosis in K562 leukemic cells. K562 leukemic cells were co-transfected with a plasmid
containing YB-1 shRNA and pEGFP. pEGFP was used as a selectable marker to establish stable
clones. (A) Three clones sh6-, sh7- & sh8- were selected and down-regulation of YB-1 was
confirmed by western blot using anti-YB-1 antibody (1µg/ml). GAPDH was used as loading
control. Approximately 40% reduction in YB-1 expression was achieved in each of these clones.
(N=3) (B) Sh6-, sh7-, & sh8- transfected K562 cells were treated with 0.5µM As2O3 for 72
hours and cell viability assay was done at 24, 48 &72 hours as described in methods (* indicate
p≤ 0.01). (C) Apoptotic analysis was done in K562 cells after 72 hr of treatment with or without
0.5µM As2O3. These cells were labeled with annexin V pacific blue and 7-AAD and then
subjected to flow cytometric analysis. Untransfected K562 cells and EV served as controls (*
indicate p≤ 0.01). Data is expressed as the mean ± SEM of triplicate samples. Data is
representative of at least two independent experiments. ANOVA for multiple pairwise
comparisons was used to analyze the data along with Student t test comparing each to untreated
cells.

51

A higher number of apoptotic cells were detected in sh6-, sh7-, sh8-K562 compared to the
normal K562 cells and EV at 72 hours. A statistically significant increase in the number of
annexin-V positive cells was seen in sh6- (61%), sh7- (57%) after treatment with 0.5 µM As2O3
for 72 hours (p<0.01) (Figure 2.6C). These data indicate that loss of YB-1 reduce cell viability in
leukemic cells, and confers some protection from apoptosis in these cells.
YB-1 down-regulation leads to the induction of megakaryocytic differentiation in sh6-,
sh7-, and sh8- in comparison to the normal K562 cells and EV at 72 hours after treatment with
0.5 µM As2O3. Phase contrast microscopic examination of As2O3 treated sh6- sh7-, and sh8K562 cells revealed an increase in the nuclear to cytoplasm ratio, and an elongated shape
characteristic of megakaryocytic morphology (Figure 2.7A). To confirm the megakaryocytic
differentiation in sh6-, sh7-, and sh8- K562 cells, CD41a (GPIIb/IIIa) expression, a marker for
platelet/megakaryocytes, was measured. Interestingly YB-1 down-regulation alone resulted in
an increase in CD41a expression. Further increase in CD41a expression was observed after 72
hours of treatment with 0.5 µM As2O3 (Figure 2.7B). Polyploidization is a unique feature of
megakaryocytes (Szalai et al., 2006). To further confirm megakaryocytic differentiation, DNA
content was measured by PI staining. Ploidy analysis revealed a significant increase in the 4 and
8N population of cells 72 hours after treatment with 0.5 µM As2O3 in sh6-, sh7-, and sh8- in
comparison to the normal K562 cells and EV (Figure 2.7C). From this data it is evident that
down-regulation of YB-1 primes the sh6-, sh7-, and sh8-K562 cells for megakaryocytic
differentiation after treatment with 0.5 µM As2O3.
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Figure 2.7. Effects of down-regulation of YB-1 expression on cell differentiation in K562
leukemic cells (A) Morphological changes in K562 cells at 72 hrs with or without treatment of
0.5µM As2O3. Arrows indicate megakaryocytic cells. Magnification is 400x. Scale bars are
50µm. (B) K562 cells were treated with or without 0.5µM As2O3 for 72 hrs and CD41a
expression which labels platelets and megakaryocytes was measured (* indicate p≤ 0.01). Data
are expressed as the mean ± SEM of triplicate samples and is representative of at least two
independent experiments. ANOVA for multiple pairwise comparisons was used to analyze the
data along with Student t test comparing each to untreated cells (C) K562 cells were treated with
or without 0.5 µM As2O3 for 72 hrs and DNA content of cells was assayed by staining with
propidium iodide (PI) and then analyzed by flow cytometry. Data is representative of at least two
independent experiments. EV indicates empty vector.
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Discussion
Y box binding protein is a multifunctional protein and is involved in regulating both
transcription and translation. YB-1 promotes cell proliferation through transactivation of target
genes such as proliferating cell nuclear antigen, epidermal growth factor receptor, DNA
topoisomerase II, thymidine kinase and DNA polymerase α (Wolfe, 1994; Ladomery and
Sommerville, 1995). It has also been implicated in cell cycle regulation, cell survival, stress
response regulation, DNA repair, and drug resistance (Lu et al., 2005; Kohno et al., 2003).
YB-1 has been shown to be involved in erythroid development through interactions
with GATA (Yokoyama et al., 2003); however the role of YB-1 in early hematopoietic
differentiation has not been investigated. For the first time, we show in this study that YB-1 is
expressed in early hematopoiesis and both YB-1 mRNA and protein levels are down-regulated
during myeloid differentiation. EML cells undergoing myeloid differentiation down-regulate
YB-1 expression after three days of culture in RA+IL-3. YB-1 expression is further downregulated at six days when these myeloid progenitors are cultured in GM-CSF with the
appearance of an increasing number of more committed granulocyte and monocyte progenitors.
A previous cDNA microarray study that analyzed changes in gene expression during induced
myeloid differentiation of EML cells showed similar results (Ma et al., 2002). This indicates
that YB-1 is highly expressed during hematopoiesis in multipotent hematopoietic precursor
EML cells but is down-regulated in more committed granulocyte/monocyte progenitors.
We have observed greater reduction in the YB-1 protein expression as compared to the
YB-1 mRNA in both RA/IL-3 and GM-CSF treated EML cells relative to the DMSO treated
EML cells.

YB-1 has been shown to regulate gene expression not only at the level of

transcription, but also at the level of mRNA translation (Fukuda et al., 2004). Therefore, lower
levels of YB-1 protein expression as compared to YB-1 mRNA might be due to autoregulation
of YB-1 translation by YB-1 mRNA. Another possibility could be that RA+IL-3 and GM-CSF
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treatment might lead to post-translation regulation of YB-1 (Wu et al., 2007). YB-1 can shuttle
between the cytosol and nucleus (Jurchott et al., 2003) and can also be localized to the
mitochondria (de Souza-Pinto et al., 2009). However, we have examined only nuclear
expression of the YB-1. Thus, a cytoplasmic fraction of YB-1 might account for the lack of
correlation between theYB-1 protein and RNA levels.
Since we found a dramatic down-regulation of YB-1 expression in EML cells during
myeloid differentiation, we investigated YB-1 expression in vivo. HSCs and progenitors were
isolated based upon the parameters lineage−/IL-7R−/c-kit+/Sca1+ (which is an enriched fraction
for HSC), lineage−/IL-7R−/c-kit+/Sca1− (myeloid progenitors). Like EML cells, we found high
expression of YB-1 mRNA levels in the stem/progenitor cells of mouse BM as compared to the
differentiated cells like granulocytes. YB-1 has a role in cell proliferation and is known to
repress transcription of genes involved in differentiation (GM-CSF) and apoptosis (Fas) so one
possible explanation for YB-1 to be down-regulated in granulocytes is to allow the expression
of differentiation factors (Coles et al., 1996; Lasham et al., 2000). A gene expression study of
mouse transcriptome agrees with this data as similar results have been shown in mouse BM for
YB-1 expression (http://biogps.gnf.org). Taken together, the EML cell studies and primary
bone marrow studies share consistent results and thus provide strong evidence that YB-1 is
highly expressed

in

stem/

early progenitor

cells

and is

down-regulated during

granulocyte/monocyte lineage differentiation.
Our data revealed a significant reduction in the YB-1 expression in EML cells upon
treatment with RA/IL-3, while we saw an increase in the YB-1 mRNA expression in myeloid
progenitors as compared to the HSC in mouse BM. This difference could be attributed to the
fact that the in vitro model involves using relatively high pharmacological concentrations of
retinoic acid (10 µM) about 100–1000-fold higher than the endogenous physiological
concentration of retinoids (1–10 nM) normally present in serum which could lead to off target
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effects (Collins, 2002). Moreover, we have differentiated EML cells towards only CFU-GM,
which generates granulocyte monocyte progenitors (GMP) while in the mouse BM we have
assayed all the myeloid progenitors as one group including common myeloid progenitor
(CMP), GMP and megakaryocyte erythroid progenitor (MEP). Possibly, YB-1 expression goes
down in the GMPs, but not in the CMP and MEP.
YB-1 has been shown to be up-regulated in the bone marrow of patients with MDS
(Lee et al., 2001; Yokoyama et al., 2003). Over-expression of YB-1 mRNA and protein is
associated with several human cancers including breast, prostate, pancreas, colorectal and
melanoma (Kohno et al., 2003), but its role in leukemia has not yet been investigated.
Therefore, cell lines derived from patients with HL-60 (acute promyelocytic leukemia), U-937
(acute promonocytic leukemia), K562, chronic myelogenous leukemia (CML) and WEHI-3
(murine monocytic leukemia), which are arrested at various stages of myeloid differentiation,
were used to analyze the expression of YB-1 protein. YB-1 protein was expressed by all the
myeloid leukemic cell lines, indicating that YB-1 is associated with myelogenous leukemia.
Additionally, it is intriguing that YB-1 was up-regulated in mouse progenitor cells as compared
to mouse HSCs. This finding is consistent with the hypothesis of the progenitor being the cell
of origin for some leukemias (Jamieson et al., 2004).
To determine the role of YB-1 in leukemia we investigated the biological consequences
of YB-1 knockdown in K562 leukemia cells. This cell line was chosen due to high expression
of YB-1. We treated cells with As2O3 because it is being used as a therapeutic agent for the
treatment of acute promyelocytic leukemia. The concentration of As2O3 used was 0.5 µM,
which is within the known plasma concentration in patients under treatment and does affect cell
viability (Tang et al., 1997). YB-1 down-regulation resulted in growth arrest and induction of
apoptosis. Upon treatment with As2O3 these effects were more pronounced. YB-1 promotes cell
proliferation by transactivating various genes involved in cell division and also by controlling
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cyclin A and B1 gene expression (Wolfe, 1994; Ladomery and Sommerville, 1995; Jurchott et
al., 2003). A few studies have reported biological effects of YB-1 (Schittek et al., 2007;
Chatterjee et al., 2008). In the multidrug resistant cell line, K562/A02 YB-1 down-regulation
leads to decreased cell proliferation and induction of apoptosis. These results are consistent
with our findings in untreated K562 cells (Xu et al., 2009).
K562 is an erythroleukemia cell line that is situated in the common progenitor stage of
megakaryocytic and erythroid lineages of hematopoietic cell differentiation. K562 cells can be
induced to erythroid or megakaryocytic differentiation by different agents (Baliga et al., 1993;
Tabilio and Pelicei, 1983). As2O3 exerts double effects on acute promyelocytic cells, i.e.,
induction of apoptosis and partial differentiation (Tang et al., 1997). Interestingly, downregulation of YB-1 and treatment with As2O3 led to megakaryocytic cell differentiation in K562
leukemia cells, further strengthenig our observation that YB-1 is associated with
stem/progenitor cell maintenance. We saw a significant change in cellular morphology after 72
hr treatment of K562 leukemic cells with As2O3; evident by an increase in nuclear size and
cytoplasmic mass. YB-1 knockdown alone resulted in an increase in CD41a, a cell surface
marker associated with megakaryocytic differentiation expression. However, we did not see
any large change in cellular morphology. After treatment with As2O3, there was a steep,
statistically significant increase in the expression of CD41a when YB-1 was downregulated in
sh6-, sh7- and sh8- K562 cells. Further confirmation of megakaryocytic differentiation was our
detection of polyploidy in K562 cells when YB-1 was downregulated (Vitrat et al., 1998). The
ability of K562 cells to partially differentiate upon YB-1 knockdown supplemented with As2O3
treatment is a novel finding.
In conclusion, our data reveals that YB-1 is highly expressed in the EML cell line but is
down-regulated upon differentiation of these cells towards the myeloid lineage. Terminally
differentiated cells, such as granulocytes, express low levels of YB-1 as compared to murine
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BM stem and progenitor cells. Expression of YB-1 in several myeloid leukemia cell lines
indicates its association with leukemia. Down-regulation of YB-1 expression reduced cell
proliferation, induced apoptosis and cell differentiation. Further studies are needed to decipher
the mechanism of how YB-1 contributes to the blockage of myeloid differentiation.
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In leukemia there is uncontrolled proliferation of immature progenitors and blockage to their
differentiation.Understanding the mechanisms involved in hematopoietic differentiation will help
in developing therapies against leukemia. Our major focus of this work was to identify different
genes that play role in hematopoietic differentiation. Hsp90 is a molecular chaperone that is
involved with protein folding and various signal transduction cascades. Hsp90 has been suggested
to regulate Wnt signaling in the Drosophila model. Wnt signaling is associated with
hematopoietic stem cell maintainenace and is important for leukemia progression. In chapter 3,
we investigated the role of Hsp90 in the regulation of Wnt signaling in mammalian hematopoietic
system.
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CHAPTER Three: Activation of the canonical Wnt pathway in
the hematopoietic precursor EML cell line upon Hsp90
inhibition
Abstract
Acute myeloid leukemia (AML) in adults has a 20% 5-year disease-free survival, despite
treatment with aggressive cytotoxic chemotherapy. Heat shock protein (Hsp90) is a chaperone
for several client proteins involved in transcriptional regulation, signal transduction and cell
cycle control. 17-AAG, the synthetic analogue of geldanamycin (GA), is an Hsp90 inhibitor that
is presently in phase II clinical trials for the treatment of various leukemia and other cancers. In
Drosophila, functional inactivation of Hsp90 resulted in a transdifferentiation event where the
eye tissue becomes a limb-like outgrowth due to abnormal wingless expression (wg). Expression
of this phenotype induced by Hsp90 inhibition becomes independent of chaperone after being
inherited across successive generations, suggesting an epigenetic mechanism. Wnt signaling is
associated with hematopoietic stem cell maintenance and is important for leukemia progression.
The objective of the study in chapter 3 was to determine whether the Wnt pathway is regulated
by Hsp90 in mammalian cells through epigenetic mechanisms as observed in flies. Our
preliminary data showed the activation of the canonical Wnt pathway in a hematopoietic
precursor cell line, EML, after inhibition of Hsp90. This effect seemed to be short lived and
pharmacological inactivation of Hsp90 did not cause any changes in the Wnt pathway activity
during myeloid differentiation of EML cells. However there was considerable variability in our
results that prevented further progress in these studies. Further investigation into the molecular
mechanism of Hsp90 inhibition and Wnt signaling in adult hematopoietic stem cells is needed to
determine whether Hsp90 play a role in maintaining the leukemic state in AML.
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Introduction
Hsp90 is a specialized molecular chaperone involved in the stress response and in
normal homoeostatic control mechanisms. Several client proteins including transcription factors
and protein kinases are Hsp90 substrates, where it facilitates their stabilization and activation.
Inhibition of Hsp90 leads to disruption of various signal transduction pathways in the cell.
Hsp90 inhibitors such as geldanamycin act by interacting specifically with a single molecular
target, the Hsp90 chaperone, thereby destabilizing and degrading Hsp90 client proteins (Pearl et
al., 2008).
Although Hsp90 is expressed in normal cells, it is frequently overexpressed in cancer
cells, suggesting a role in maintaining malignant transformation. Hsp90 has been implicated in
oncogenesis by associating with multiple mutated, chimeric and over expressed signaling
proteins that promote cancer cell growth and survival (Pearl et al., 2008). Several studies have
shown that Hsp90 inhibitors target tumor cells over normal cells because of higher binding
affinity of the Hsp90 complexes present in these tumor cells (Chen et al., 2010; Flandrin et al.,
2008). Thus targeting Hsp90 could result in simultaneous disruption of multiple oncogenic
signal transduction pathways suggesting utility for treatment of advanced cancers.
According to Waddington’s canalization model there are masked phenotypes in a wildtype population which can be expressed during environment stress. When these adaptive
phenotypes are selected over subsequent generations they get fixed and can be expressed even
in the absence of stress (Waddington, 1942). Under stressful conditions Hsp90 deviates from its
usual role of activating signal transduction proteins and severe stress can temporarily
overwhelm the Hsp90 chaperone system. This leads to generation of varied phenotypes, which
when selected, can be fixed in the population and are significant in terms of evolution (Wong
and Houry, 2006). Impairment of Hsp83, the Drosophila homolog of Hsp90 produced abnormal
phenotypes which are inherited in subsequent generations (Rutherford et al., 1998). Thus
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Hsp90 can act as genetic capacitor by storing masked phenotypes for later release.
This impairment of Hsp90 either by genetic mutation or pharmacological inhibition in
Drosophila led to phenotypic variation was also reported by another study. However, an
epigenetic basis for the capacitor function of Hsp90 was revealed, as depletion of Hsp90
induced an altered chromatin state. Progeny of flies which were fed Hsp90 inhibitor,
geldanamycin (GA) and a mutation in the trithorax group of genes (TrxG) showed an abnormal
eye-bristle phenotype. Interestingly, phenotypic selection of this drug-induced phenotype
resulted in an increase in the number of affected progeny in successive generations even in the
absence of Hsp90 inhibition indicating, an epigenetic mechanism. Further evidence for an
epigenetic phenomenon came from chromatin remodeling inhibitors, which were able to reverse
this phenotype (Sollars et al., 2003).
Moreover, it was found that this abnormal eye phenotype induced by Hsp 83 and TrxG
mutations was due to ectopic expression of Wingless (wg) (Sollars et al., 2003). Wingless is
required for many developmental processes ranging from embryonic segmentation to limb
development. Since mutations in TrxG genes induced up-regulation of the Wnt pathway, this
indicates a role of epigenetic gene regulation in this pathway.
The Wnt signaling pathway is highly conserved during evolution and regulates
hematopoietic stem cell maintenance and self renewal (Kirsttetter et al., 2006). Its
dysregulation is responsible for various hematological malignancies including leukemia. The
canonical Wnt pathway regulates target gene expression via the stabilization and nuclear
translocation of the cytoplasmic pool of ß-catenin (Brembeck et al., 2003). The focus of this
study was to find out whether Hsp90 modulation can regulate the Wnt pathway epigenetically
in a mammalian model system.
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Hematopoiesis is an excellent model to study differentiation due to the presence of
different cell surface markers along the course of development. The Erythroid Myeloid
Lymphoid clone 1 (EML) cell line was developed from murine bone marrow cells transfected
with a vector expressing a dominant negative form of retinoic acid receptor. These cells are a
unique in vitro model to study hematopoietic differentiation. EML cells can be indefinitely
propagated in medium containing stem cell factor (SCF) and can be differentiated into erythoid,
myeloid and lymphoid lineages by the addition of appropriate cytokines (Tsai et al., 1994).
Our hypothesis was that Hsp90 acts as an epigenetic modulator affecting the Wnt
pathway in the EML cell model. To test this hypothesis, EML cells were treated with GA and
Wnt pathway activation was examined based upon ß-catenin accumulation and translocation to
the nucleus.

Materials and Methods
Materials
Geldanamycin, GA (G3381) and retinoic acid (R2625) were purchased from Sigma.
FITC conjugated total ß-catenin (610155) and Fc Blocker (553142) antibodies were purchased
from BD Biosciences while active ß-catenin (05-665) was purchased from Millipore.
Paraformaldehyde (15014601) and Triton X-100 (02300221) were bought from MP
Biomedicals. GM-CSF was purchased from Stem Cell technologies (Vancouver, BC).
Cell culture
EML C1 cells were the kind gift of Dr. Schickwann Tsai and were maintained in growth
medium which is base medium (IMDM supplemented with 20% heat inactivated horse serum,
American Type Culture Collection, ATCC, Manassas, VA) and 10% BHK/MKL-conditioned
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medium, (Tsai et al., 1994). EML cells were maintained at a density below 5 x 105 cells/ml for
these experiments. BHK cells were cultured in EMEM and WEHI-3 cells (TIB-68, ATCC)
were cultured in IMDM supplemented with 10% FBS at 37º C and 5% CO2. L Cells
(immortalized mouse fibroblast) were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (ATCC, CRL-2648). L-Wnt 3a cells, the
Wnt 3a expressing clone of L cells and L-Wnt 5a, the Wnt 5a expressing clone of L cells
(ATCC, CRL-2647 and 2814), were maintained in the same medium containing 0.5 mg/ml of
G418.
EML cell differentiation
EML cells were seeded at a density of 1x105 cells/ml in base medium along with 10µM
all-trans retinoic acid (ATRA; sigma, St. Louis, MO, USA), 10% BHK conditioned medium
(source of stem cell factor) and 15% WEHI conditioned medium (source of interleukin-3) for
three days. Cells were then washed twice with PBS and resuspended at 1x106 cells/ml in base
medium with 20 ng/ml of murine granulocyte-monocyte colony stimulating factor (GM-CSF)
(Stem Cell Technologies, Vancouver, BC, Canada) for the next three days.
Treatment with Geldanamycin (GA)
EML cells were seeded at 2x105 cells/ml in growth medium and treated with 5, 10 or 15
nM GA for 24 hours. DMSO was used as a vehicle. Cells were washed and reseeded at 2x105
cells/ml in growth medium after 24 hours of treatment followed by a 24 hour recovery period.
All the experiments were performed after the 24 hour recovery period.
Flow Cytometry
Treated as well as untreated L, L-Wnt3a, L-Wnt 5a and EML cells were washed twice
with FACS buffer (Phosphate buffered saline, (PBS) supplemented with 3% BSA, 0.02% sodium
azide and 1 mM EDTA) and collected by centrifugation. Thereafter they were incubated with
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FcγRII/III receptor (553142, BD Pharmingen) to prevent nonspecific binding by blocking the Fc
receptors for half an hour at 4°C. Cells were then fixed with 4% paraformaldehyde /PBS for half
an hour and permeabilized with wash buffer (PBS supplemented with 3% BSA, 0.1% Triton X100). After washing the cells in buffer they were then labeled with FITC conjugated total ßcatenin antibody (610155, BD Transduction) for half an hour at 4º C. An isotype antibody labeled
with FITC was used as a negative control for FITC. Data acquisition was performed using BD
FACS Aria sorter and data analysis was done using Flow Jo software v.7.5.5 (Treestar, Ashland,
OR).

Western blot
Treated cells from different experiments were rinsed once with ice-cold PBS and whole
cell protein extracts were obtained by briefly sonicating the cell pellets and then boiling the
lysates for 5 minutes in sample lysis buffer containing 50 mM Tris (tris hydroxymethyl
aminomethane; pH 6.8), 1% sodium dodecyl sulfate (SDS), 10% glycerol and 1 mM dithiothreitol
(DTT). Nuclear and cytoplasmic fractions were separated using the NE-PER extraction kit as per
the manufacturer’s instructions (Pierce, Rockford, IL). Protein concentration was determined
using bicinchoninic acid (BCA) protein assay reagents from Pierce according to the
manufacturer’s guidelines. Cell extracts were then denatured at 95°C for 5 min in 2x sample
buffer (62.5 mM Tris HCl, pH 6.8, 25% glycerol, 0.01% bromophenol blue, 2% SDS,10% βmercaptoethanol). Equal amount of protein extracts were separated on an 8-16% gradient TrisGlycine SDS–poly acrylamide gel (Bio-Rad, Hercules, CA) by electrophoresis (PAGE) and
transferred onto nitrocellulose membranes (Millipore) using Bio-Rad MiniProtean3® system. The
membranes were treated in blocking solution (5% non fat dry milk in TBS containing 0.1%
Tween 20) and incubated with primary active ß-catenin antibody (05-665, Millipore, 1 µg/ml)
overnight at 4°C, followed by incubation with HRP-conjugated monoclonal mouse secondary
IgG antibody (1: 3000, 7074, GE Healthcare, CT). An anti-mouse GAPDH antibody (MAB374,
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GE Healthcare, CT) was used to assess equal loading. Proteins were visualized by ECL (GE
Healthcare, CT). A Benchmark TM protein ladder was used to visualize the transfer of protein onto
the membrane and MagicMark TM XP (Invitrogen) was used as a molecular size standard.

Results
EML cells have high total ß-catenin levels
Wnt signaling is important in embryogenesis and is required for the maintenance of the
hematopoietic stem cell state (Reya et al., 2003). The canonical Wnt pathway involves the
stabilization and nuclear accumulation of its downstream target, ß-catenin (Mc Donald et al.,
2006). In order to determine the activity of Wnt signaling in the hematopoietic precursor cell
line EML, we performed intracellular staining to assess the ß-catenin accumulation.

Figure 3.1 High β-catenin accumulation in EML cells. Intracellular staining was done to
examine the level of total β-catenin protein in EML cells. Increased β- catenin accumulation is
present in EML (purple) cells in comparison with other cell types normal L cells (brown), Wnt
3a (green) which have active canonical Wnt pathway due to secretion of Wnt in the medium.
Noncanonical Wnt 5a (red) expressing cells do not appear to show any accumulation of βcatenin. FITC mean fluroscence values are listed in the figure. L-cells +ve is labeled with FITC
conjugated β- catenin antibody.
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EML cells showed higher ß-catenin accumulation compared to normal L cells, Wnt 3a L
and Wnt 5a L cells (Figure 3.1). Wnt 3a transfected cells were used as a positive control for
active canonical Wnt signaling and Wnt 5a as a positive control for non-canonical Wnt
signaling. However, L cells represented basal levels of ß-catenin, which is expected because of
its role in the cytoskeleton (Brembeck et al., 2006). The signal intensity of ß-catenin was twofold higher in EML cells relative to Wnt 3a-L cells. The Wnt 5a expressing cells do not appear
to show any accumulation of ß-catenin as the signal intensity of ß-catenin was similar in them
relative to the L cells.

Hsp90 inhibition leads to reduction in total ß-catenin levels in EML cells
Functional inactivation of Hsp90 led to a transdifferentiation event in successive
generations of Drosophila due to epigenetic regulation. This transdifferentiation event in
Drosophila also led to abnormal activation of Wnt signaling (Sollars et al., 2003). My study was
aimed at ascertaining whether in a mammalian model Hsp90 regulates the Wnt pathway through
an epigenetic mechanism. A hematopoietic precursor cell line, EML, was used as a
representative mammalian model system. Since the half life of Hsp90 dissociation and biological
persistence is short (Supko et al., 1995), and EML cells undergo one cellular division during the
24 hour rest period, a protocol of pharmacological inhibition followed by a recovery period will
help in analyzing epigenetic effects. Our goal is to achieve an epigenetic phenotype for the EML
cells which will be analyzed in future experiments. Before testing the epigenetic mechanism we
wanted to examine the effect of Hsp90 inhibition on the Wnt singaling. Thus, EML cells were
treated with GA for 24 hours followed by a 24 hour rest period before determining the
accumulation of ß-catenin. We observed a decrease in total ß-catenin levels after GA treatment,
indicated by both the reduction in the percentage positive as well as the median fluorescence of
total ß-catenin (Figure 3.2). There was more than a 40%, statistically significant reduction of
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signal intensity for total ß-catenin in 10 nM GA treated EML cells relative to control.

A

B

Figure 3.2 Decrease in total β-catenin protein in EML cells after Hsp90 inhibition. EML
cells were exposed to vehicle (DMSO), 5 nM or 10 nM GA for 24 hours. The cells were then
allowed to recover for 24 hours, and β-catenin levels were analysed using flow cytometry. Total
volume of DMSO was constant in all trials. (A) shows the percentage of EML cells which were
positive for β-catenin (*p value < 0.01). (B) shows the median fluorescence values for βcatenin protein (**p value < 0.05) (N=3).

Activation of the canonical Wnt pathway after inhibition of Hsp90 in EML cells
In the absence of phosphorylation by glycogen synthase kinase (GSK3 ß), ß-catenin is
stabilized referred to as active ß-catenin, which translocates to the nucleus, an indication of
active Wnt signaling (Van Noort M et al., 2002). Since total ß-catenin levels are not an accurate
representation of the activation of Wnt pathway we wanted to determine the effect of Hsp90
inhibition on the active ß-catenin levels in EML cells by western blotting. When we treated
EML cells with different concentrations of GA, we found that active ß-catenin protein was
highly expressed in 10 nM GA treated EML cells relative to vehicle control and 15 nM GA
treated EML cells (Figure 3.3 A).
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To further determine the effect of 10 nM GA on ß-catenin levels and to determine how
long the Wnt pathway remains activated, we did a time course study. It seemed that the upregulation in the levels of active ß-catenin protein lasted for only 24 hours (Figure 3.3 B). In
this figure, ponceau staining was used as a loading control. This data suggests that the Wnt
pathway might be activated after the inhibition of Hsp90 in EML cells, but if this does occur it
is of a short duration.

A

B

Figure 3.3 Activation of the Wnt pathway after inhibition of Hsp90 in EML cells. (A) EML
cells were treated with vehicle, 10 and 15 nM GA for 24 hours and rested for another 24 hours.
Whole cell lysates were extracted and analyzed by western blot analysis to detect active βcatenin protein levels. Ponceau staining was done to determine equal loading. This blot is
representative of two independent experiments. (B) EML cells were treated with 10 nM GA for
24 hours and followed by a 24 hour rest period as before. Western blot was done on the whole
cell extracts at 24, 48, 72 hours and 1 week time course. ‘C’ represents the vehicle control. This
blot is representative of two independent experiments.

Loss of Wnt pathway activation in GA treated EML cells after differentiation
We wanted to observe whether our preliminary finding of the up-regulation in Wnt
signaling due to Hsp90 inhibition (Fig. 3.3) results in changes in the expression of ß-catenin
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after differentiation of EML cells. Therefore, we inhibited Hsp90 and then forced EML cells to
differentiate toward the granulocyte macrophage pathway by treating them with RA and
GMCSF.
A

B

Figure 3.4 Wnt pathway activation in GA treated EML cells after differentiation. (A)
EML cells were treated with 10 nM GA for 24 hours and rested for another 24 hours before
proceeding with the differentiation protocol. Nuclear extracts were isolated and western blot
analysis was done to determine the levels of active β-catenin after treatment with RA and
GMCSF. This is a representative blot for two independent experiments. (B) EML cells were
treated with 10 nM GA and then a second dose of 5 nM given during our differentiation
protocol along with treatment with RA and IL-3. Western blot analysis was done after
extraction of nuclear extracts to examine the levels of active β-catenin. GAPDH was used as a
loading control. This is a representative blot for two independent experiments. ‘C’ represents
the vehicle control.

In this experiment, Hsp90 inhibition did not show any effect on the active ß-catenin
expression. Secondly, we found that upon differentiation with RA as well as GMCSF in the
EML cells activity of ß-catenin was inhibited regardless of Hsp90 inhibition (Figure 3.4A).
This data suggests that Hsp90 inhibition does not seem to play a role in Wnt pathway activation
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with or without forced differentiation of EML cells. Next, we tried to modify our treatment
protocol by giving a second dose of GA during differentiation but that also seem to have no
effect on the levels of active ß-catenin (Figure 3.4B).

Wnt pathway activation through inhibition of Hsp90 in EML cells was not consistent
Next, we wanted to reproduce the earlier findings of Hsp90 inhibition on ß-catenin
activity in EML cells. Therefore, EML cells were treated with various concentration of GA for
24 hours and active ß-catenin levels were measured by western blot.
A

B

Figure 3.5 Up-regulation of Wnt signaling observed previously was not consistent. (A)
EML cells were treated with vehicle, 1, 2, 5 or 10nM GA for 24 hours followed by a 24 hour rest
period. Nuclear extracts were isolated and active ß-catenin levels were measured. GAPDH was
used as a loading control. This blot is representative of at least three different experiments. ‘C’
represents the vehicle control. (B) The densitometric analysis for the above experiment.
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We found that there was no significant difference in the active ß-catenin levels between
the vehicle control relative to GA treated EML cells (Figure 3.5). This data indicates that the upregulation of Wnt signaling upon Hsp90 inhibition in EML cells as observed in our preliminary
studies is inconsistent.
Discussion
We observed an increased expression of ß-catenin in EML cells compared to the L-Wnt
3a cells, which have active canonical Wnt signaling. This is consistent with the fact that EML
cells are stem cell in nature and the self renewal pathway such as canonical Wnt signaling is
required for maintenance of a hematopoietic stem cell state. Deregulation of Wnt signaling,
which is normally tightly regulated, has been identified as an important step in leukemic
transformation. Common myeloid progenitor (CMP) gives rise to granulocyte macrophage
progenitor (GMP) which can form either granulocytes or macrophages that have an active Wnt/
ß-catenin pathway. The GMP has elevated levels of nuclear ß-catenin and has been identified as
candidate leukemic stem cell in blast crisis chronic myelogenous leukemia (Jamieson et al.,
2004). Moreover mutations in members of the Wnt -ß- catenin pathway occur in 90% of the
colorectal cancers and other cancers such as hepatocellular and gastric cancers (Brembeck et
al., 2006).
In EML cells, after inhibiting Hsp90, we saw a down-regulation of total ß-catenin
expression in contrast to what was observed in Drosophila. Hsp90 inhibitors have been shown
to have higher binding affinity to tumor cells than normal cells leading, to proteosomal
degradation of Hsp90 client proteins. However, several studies have also demonstrated the toxic
effects of Hsp90 inhibitors on the normal cells. In two different studies, Hsp90 inhibitors were
found to be extremely cytotoxic to the Oligodendrocyte precursor cells (OPCs) and human
retinal pigment epithelial cells respectively in vitro (Alcazar and Cid, 2009; Wu et al., 2010). In
another study, it has been shown that the Hsp90 inhibitor geldanamycin and its analogs have
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cytotoxic effects on rat primary hepatocytes due to generation of reactive oxygen species
(Samuni et al., 2010). Therfore Hsp90 inhibitors might be toxic to EML cells and this toxicity
can result in a general down-regulation of protein expression and a lowering of ß-catenin
protein levels. Moreover, given the role of Hsp90 in diverse biologic processes, drugs targeting
Hsp90 will have side effects on normal cellular function.
Canonical Wnt pathway activation is achieved by stabilization of ß-catenin and
translocation to the nucleus, activating the transcription of target genes responsible for cellular
proliferation and differentiation (Brembeck et al., 2006). Therefore we measured the amount of
active ß-catenin that is due to dephosphorylated on Ser 37 or Thr41 of the molecule (Fig. 3.3
and 3.4). Surprisingly, we saw an increase in active ß-catenin levels after inhibition of Hsp90 in
EML cells, which is contradictory to what we previously found. This could be explained by the
fact that ß-catenin is also involved in cell-cell adhesion at the plasma membrane by mediating
association of integrins with intracellular actins in myeloid cells (Brembeck et al., 2006).
Inhibition of Hsp90 affects both the transcriptional regulation and cellular adhesion functions of
ß-catenin. Also, Hsp90 is required for constitutive and inducible activity of the IKB kinase
(IKK) complex (Broemer et al., 2002). Therefore, inhibition of Hsp90 results in impairment of
IKK activity. IKK regulates ß-catenin via phosphorylation and ubiquitin dependent degradation.
It has been shown that IKK ß decreases ß –catenin dependent gene expression similar to the
effects seen with GSK-3 ß (Lamberti et al., 2001). In addition, the up-regulation in Wnt
signaling upon Hsp90 inhibition in EML cells is consistent with the previous finding of
increased Wg expression in Drosophila upon Hsp90 inhibition (Sollars et al., 2003).
The up-regulation of Wnt signaling upon Hsp90 inhibiton in EML cells lasted only for
short duration. The half life of the Hsp90- GA complex is short, indicating Hsp90 inactivation
is short-lived once GA is no longer supplied to the EML cells. Also the biological half life of
GA in mice is 77.7 minutes (Supko et al., 1995), which means it is rapidly degraded. Since the
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biological persistence of Hsp90 is short, it is not surprising that the up-regulation in Wnt
signalling was short-lived.
We did not observe any changes in the active ß-catenin levels upon Hsp90 inhibition in
differentiating EML cells. This could be due to the fact that we did not see an effect of Hsp90
inhibition in the control and GA treated EML cells in this experiment. Interestingly, we found
that active ß-catenin was not expressed in differentiating EML cells. This is consistent with the
observation that Wnt signaling is involved in the maintenance and renewal of hematopoietic
progenitors/stem cells and inhibition of Wnt pathway induces their differentiation (Kirstetter et
al., 2006). Also, it has been shown that expression of a mutant active ß-catenin in normal
progenitors impairs myelomonocytic differentiation (Simon et al., 2005).
Future experiments focused on attaining the inhibition of Hsp90 by treating EML cells
with varying doses of GA. It was thought that the effect on the Wnt signaling might be seen at
different concentration of GA. We also tried to use early passaged EML cells for our
experiments. Moreover a longer rest period was given to EML cells after GA treatment. But our
repeated attempts to revive the phenotype were unsuccessful and there was no significant
difference in the active ß- catenin levels in the vehicle and GA treated EML cells. Another
study conducted in our lab to look at the effect of Hsp90 inhibition on the myeloid cell
differentiation also indicated variable results and no effect on the differentiation profile of EML
cells (Napper, 2010). This could be attributed to the fact that inhibition of Hsp90 might not
have any effect on the Wnt signaling at least in the in vitro EML cell model.
Two earlier studies have reported that EML cells are a heterogenous population. In one
study the authors demonstrated that can be separated into two different populations based on
CD34 expression. Levels of stem cell factor receptor (c-kit) are similar in both these
populations but they differ in growth characteristics and response to cytokines. The CD34+
population shows a growth response when treated with SCF while the CD34- population grew
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in the presence of IL-3.The CD34+ population is able to regenerate the mixed population upon
stimulation with SCF (Ye et al., 2005). Another study demonstrated the broad spectrum of Sca1 expression in EML cells, which was enlisted as the cause of clonal subpopulations in these
cells. Both high and low Sca-1 expression populations were able to reconstitute the parental
distribution of Sca-1. Most strikingly, the cells at the extremes of the spectrum differed in their
differentiation potential. Sca-1+cells were strongly biased toward myeloid differentiation while
Sca-1- cells toward erythroid differentiation (Chang et al., 2008). These studies indicate that
EML cells are a heterogeneous population having different populations with phenotypic cell-tocell variability. This is consistent with the notion that hematopoietic cells have an intrinsic
ability that generates a spectrum of progeny with different differentiation biases, resulting in
commitment either spontaneously or as a consequence of extracellular signals. This
heterogeneity might be attributed to biological noise, which is the fluctuation of transcriptional
regulators.
The Wnt signaling pathway controls hematopoietic stem cell (HSC) self-renewal and
differentiation of hematopoietic progenitors. Aberrant Wnt signaling is associated with
leukemia. Researchers have focused recently on the dietary fatty acids due to their beneficial
effects on health and disease. Omega fatty acids have been shown to promote myeloid cell
differentiation. Therefore, in the studies described in the next chapter, I have investigated the
effect of omega fatty acids on Wnt signaling in the hematopoietic stem cell model.
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Chapter Four: Effect of omega-3 and 6 fatty acids on the
Wnt signaling in hematopoietic precursor, EML cell line
Abstract

The pro-inflammatory omega-6 fatty acids are metabolized through the cyclooxygenase
(COX) pathway into inflammatory eicosanoids, including prostaglandin E2. In contrast, omega3 fatty acids exhibit their anti-inflammatory properties by competitively inhibiting the
arachidonic acid (AA) cascade, mainly at the COX pathway. The Wnt signalling pathway has a
key function in stem cell maintenance and differentiation of haematopoietic progenitors and is
involved in leukemia progression. Omega-3 FAs have been shown to promote differentiation
and induce apoptosis in different cell lines. The objective of this study was to determine
whether omega FA altered Wnt signaling in a hematopoietic stem cell model. Our preliminary
data suggested that treatment of a lymphohematopoietic stem cell line, EML, with
eicosapentanoic acid, EPA (omega-3 FA) might lead to the down-regulation of Wnt signaling
compared to treatment with arachidonic acid, AA (omega-6 FA). Interestingly, similar results
were seen when promonocytic leukemic HL-60 cells were treated with omega-3 FA.
Unfortunately, these changes were not consistent and more investigation needs to be done to
standardize the experimental conditions required to obtain reproducible changes in cells treated
with omega-3 FA.
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Introduction
Omega-6 fatty acids (FA) are derived from linolenic acid (LA, 18:2) and omegas 3 FA
are derived from α-linolenic acids (ALA, 18:3). Linolenic acid and α-linolenic FA are essential
FAs that cannot be synthesized in the body and have to be obtained from the diet (Das, 2008).
Both omega-6 and omega-3 fatty acids (FA) are metabolized by the same set of enzymes to
their respective long-chain metabolites. However, the metabolic products of each pathway are
structurally and functionally distinct. LA is metabolized to arachidonic acid (AA, 20:4, omega6), while ALA can be metabolized to eicosapentaenoic acid (EPA, 20:5, omega-3) and
ultimately docosahexanoic acid (DHA, 22:6, omega-3). Alternatively, AA can be obtained from
animal fat sources and EPA and DHA can be consumed directly from marine sources
(Anderson and Ma., 2009).
EPA exhibits anti-inflammatory properties while AA has pro-inflammatory action.
EPA and AA exert these effects as they are the substrates for the synthesis of a group of antiand pro-inflammatory mediators respectively including thromboxanes, leukotrienes, and
prostaglandins, collectively referred to as eicosanoids, via the cyclooxygenase (COX) and
lipoxygenase pathway(Anderson and Ma, 2009).
The ratio of omega-6 to omega-3 FAs is believed to be of higher importance than the
absolute levels of a particular fatty acid and is thought to play a role in inflammatory, heart, and
metabolic diseases, as well as cancer (Gleissman et al., 2010). Impaired differentiation is the
hallmark of many forms of cancer, but is particularly pronounced in myeloid leukemias.
Omega-3 FA have been shown to promote differentiation by affecting myeloid progenitor cell
frequency (Dupuis et al., 1997; Varney et al., 2009) and thus can be potentially used as a
therapy in myeloid leukemias.
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The Wnt signaling pathway controls hematopoietic stem cell (HSC) self-renewal and
bone marrow repopulation; aberrant Wnt signaling is associated with carcinogenesis (Jamieson
et al., 2004; Brembeck et al., 2006). It has been shown in previous studies using the Drosophila
model system that the Wnt pathway can be epigenetically regulated (Sollars et al., 2003). In
these studies mutations in trithorax group of genes or Hsp90 resulted in the gain of function
expression of wingless, which was epigenetically inherited. It is thought that epigenetic silencing
of secreted frizzled related proteins (SFRP) that have been implicated in colorectal cancer,
results in the accumulation of the Wnt ligand and activated signaling (Suzuki et al., 2004). Also,
Wnt activation in stem cells requires PGE2, a byproduct of AA metabolism (omega-6 FA).
Inhibition of PGE2 synthesis blocks alterations in HSC formation at the level of ß-catenin Wntinduced (Goeslling, 2009). Omega-3 FAs have been shown to inhibit COX-2 derived PGE2 and
Wnt/ß-catenin signaling in hepatocellular and cholangiocarcinoma (Lim et al., 2008; Lim et al.,
2009).
Thus, I hypothesize that high omega-3 FAs might inhibit leukemic progression by
inducing differentiation via down-regulation of the Wnt pathway. We used EML cells as a
model to study hematopoietic differentiation and determined the effect of exposure to various
ratios of omega-3 and 6 FA on Wnt pathway activation. Wnt pathway activation was measured
by the nuclear accumulation, ß-catenin.

Materials and Methods
Materials
Arachdonic acid, AA (A3555), Eicosapentanoic acid, EPA (E2011) and fatty acid free
bovine serum albumin, BSA (A3782) were purchased from Sigma. Active ß-catenin antibody
(05-665) was purchased from Millipore.
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Cell culture
EML C1 cells (American Type culture collection, ATCC, Manassas, VA) were
maintained in growth medium which is base medium (IMDM supplemented with 20% heat
inactivated horse serum and 10% BHK/MKL-conditioned medium, (Tsai S et al., 1994). HL-60
cells (ATCC, Manassas, VA) were cultured in IMDM and 20% FBS while U-937 cells were
cultured in RPMI supplemented with 10% FBS at 37º C and 5% CO2.

Fatty acid Treatments
EML cells were seeded at 2x105 cells/ml in growth medium and treated with 60µM fatty
acids including high AA (AA: EPA; 9:1), equal (AA: EPA; 1:1), high EPA (AA: EPA; 1:9)
dissolved in vehicle (ethanol) for 96 hours. After 48 hours cells were washed with PBS and the
same concentration of fatty acids was resupplemented along with the culture medium.

Immunoblotting
Nuclear and cytoplasmic fractions were separated using the NE-PER extraction kit as
per the manufacturer’s instructions (Pierce, Rockford, IL). Protein concentration was
determined using bicinchoninic acid (BCA) protein assay reagents from Pierce according to the
manufacturer’s guidelines. Cell extracts were then denatured at 95°C for 5 min in 2x sample
buffer (62.5 mM Tris HCl (pH 6.8), 25% glycerol, 0.01% bromophenol blue, 2% SDS,10% βmercaptoethanol). Equal amount of protein extracts were separated on an 8-16% gradient TrisGlycine SDS–poly acrylamide gel (Bio-Rad, Hercules, CA) by electrophoresis (PAGE) and
transferred onto nitrocellulose membranes (Millipore) using Bio-Rad MiniProtean3® system.
The membranes were treated in blocking solution (5% non fat dry milk in TBS containing 0.1%
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Tween 20) and incubated with primary active ß-catenin antibody (05-665, Millipore, 1µg/ml)
overnight at 4°C, followed by incubation with HRP-conjugated monoclonal mouse secondary
IgG antibody (1: 3000, 7074, GE Healthcare,CT). An anti-mouse GAPDH antibody (MAB374,
GE Healthcare, CT) was used to assess equal loading. Proteins were visualized by ECL (GE
Healthcare, CT). Benchmark TM protein ladder was used to visualize the transfer of protein onto
the membrane and MagicMark TM XP (Invitrogen) was used as a molecular size standard.

Results
Omega-3 fatty acids downregulate Wnt signaling in EML and HL- 60 cells
Wnt signaling is involved in maintaining the stem cell state in the hematopoietic system
(Brembeck et al., 2006). Omega-3 FAs have been shown to promote myeloid differentiation
(Dupuis et al., 1997, Varney et al., 2009). Also, omega-3 FAs have been reported to induce
differentiation in breast cancer (Wang et al., 2000) and inhibit Wnt signaling in other cancers
(Lim et al., 2008; Lim et al., 2009). To determine the effects of omega FAs on Wnt signaling in
the hematopoietic system we used EML cells as a model. The EML cell line was established
from DBA/2 mouse bone marrow infected with a retroviral vector (LRARα403SN) harboring a
dominant negative retinoic acid receptor (RAR construct) (Tsai et al., 1994). It is a stem cell
factor dependent multipotent cell line with myeloid, erythroid and lymphoid potential and
serves as an excellent model to study the hematopoietic system. A concentration of 60 µM was
chosen for all FAs (Finstad et al., 1998; Finstad et al., 2000). EML cells were treated with
different ratios of omega-3 (EPA) and 6 (AA) FAs. The effect of omega FA on the Wnt
signaling in EML cells was analyzed based on active ß-catenin accumulation in the nucleus. A
96 hour time point was chosen for our studies based on the preliminary data showing the
effective loading of fatty acid on the cell membrane by gas chromatography. High omega-3 FA

80

treated EML cells showed reduction in active ß-catenin levels relative to high omega-6 treated
cells (Figure 4.1A).
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Figure 4.1. Omega-3 fatty acids downregulate Wnt signaling in EML and HL- 60 cells.
Cells were exposed to vehicle, high AA (omega-6) (AA: EPA; 9:1), equal ratio of AA and EPA
(omega-6+omega-3) (AA: EPA; 1:1), high EPA (omega-3) (AA: EPA; 1:9) for 96 hours.
Thereafter, cells were washed with PBS and resupplemented with respective FA after 48 hours.
Nuclear extracts were isolated and western blot was done to determine the levels of active βcatenin. Each panel shows a representative blot (A) EML cells (B) HL-60 cells. At the bottom
of each blot is the densitometric analysis for that blot. Each blot is representative of two
independent experiments. A549 cell lysate was used as a positive control for active ß-catenin
and is represented as +ve control.

Activated Wnt signaling is involved in many forms of cancer including acute and
chronic myeloid leukemia (Wang et al., 2010; Jamieson et al., 2004). Therefore, we examined
the effect of omega fatty acids on Wnt signaling in HL-60, a human promyelocyte leukemic cell
line. HL- 60 cells were treated with different ratios of EPA and AA as described above and ßcatenin accumulation was assayed by western blot analysis (Figure 4.1B). Our data suggested
the down-regulation of active ß-catenin levels in high omega-3 FA treated HL-60 cells relative
to high omega-6 treatment
This data indicates that the Wnt pathway is inhibited upon treatment with omega-3 fatty
acids in hematopoietic stem cell culture as well as the leukemic HL-60 cell line.

Down-regulation of Wnt signaling by omega-3 fatty acids in EML, HL-60 and U-937 cells
was inconsistent
Unfortunately when further experiments were done to understand the significance of the
above data we found conflicting results. We did not see any significant difference between the
levels of active ß-catenin in high omega-3 FA treated relative to high omega-6 FA treated EML
cells (Figure 4.2 A).
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Figure 4.2. Down-regulation of Wnt signaling by omega-3 fatty acids in EML, HL-60 and
U-937 cells was inconsistent. EML cells were exposed to vehicle, high AA (omega-6) (AA:
EPA; 9:1), equal ratio of AA and EPA (omega-6+omega-3) (AA: EPA; 1:1), high EPA (omega3) (AA: EPA; 1:9) for 96 hours. Cells were washed with PBS and resupplemented with
respective FA after 48 hours. Nuclear extracts were isolated and western blot was done to
determine the levels of active β-catenin. Each panel shows a representative blot (A) EML (B)
HL-60 C) U-937. At the bottom of each blot is the densitometric analysis for that blot. Each
blot is representative of two independent experiments.A549 cell lysate was used as a positive
control for active ß-catenin and is represented as +ve control.

Similarly, the preliminary data showing that Wnt signaling might be downregulated in
omega-3 FA treated relative to omega-6 FA treated HL-60 cells was not reproducible (Figure 4.2
B). We looked at the effects of omega fatty acid treatment in another monocyte like leukemia
cell line, U-937, but we found no difference in the level of active ß-catenin expression in omega3 FA treated versus high omega-6 FA treated U-937 cells (Figure 4.2 C)
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Attempts to achieve the reduction in the Wnt signaling seen previously upon omega-3 fatty
acid treatment were unsuccessful
We wanted to standardize our treatment protocol with omega FAs. Therefore, we used
different methods to treat EML cells with omega FA to see if there was an effect on Wnt
signaling. Some studies had demonstrated the use of EPA/AA with sodium salt as a base
(Asano et al., 1997; Seung Kim et al., 2001; Edwards et al., 2004). Therefore, we treated EML
cells with sodium salts of EPA and AA but did not observe any significant difference in the
active ß-catenin levels in omega-3 and omega-6 FA treated EML cells (data not shown). Other
studies reported the treatment of cells after serum starvation with FAs along with bovine serum
albumin (BSA) (Melki and Abumrad, 1992; Ishola et al., 2006). To test this protocol, EML
cells were serum starved for 24 hours and then treated with AA or EPA complexed to bovine
serum albumin (BSA) at a molar ratio of 4:1 (FA/BSA) to a final concentration of 60µmol/L for
5 hours. Interestingly, treatment of FA itself led to massive mortality in EML cells. We also
used variable molar ratios of FA/BSA; 2:1 and 1:1. Further, after serum starvation for 24 hours
we supplemented EML cells with reduced concentration of serum (5, 10, and 15%) treated with
AA and EPA and performed cell viability assay after 24 and 48 hours (Fig. 4.3). There was
significant mortality in EML cells treated with FAs relative to vehicle control, but this effect
was more pronounced in omega-6 compared to omega-3 FA treated EML cells. We speculated
that omega FAs treated cells might be differentiating and may need a stimulant like IL-3 for
survival. More investigation needs to be done to find a protocol for treating EML and leukemic
cell lines with omega fatty acids that will yield consistent results.
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Figure 4.3. Attempts to achieve the reduction in the Wnt signaling seen previously upon
omega-3 fatty acid treatment were unsuccessful. EML cells were serum starved for 24 hours
and then treated with vehicle, high AA (omega-6) (AA: EPA; 9:1), equal ratios of AA and EPA
(omega-6+omega-3) (AA: EPA; 1:1), high EPA (omega-3) (AA: EPA; 1:9) in 5, 10 and 15%
horse serum. Cell counts were performed by trypan blue dye exclusion method at 24 and 48
hours after the treatment.
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Discussion
EML cells are stem cell in nature and have an active Wnt signaling pathway indicated
by the nuclear translocation of active ß-catenin. Wnt signaling regulates stem cell fate in the
hematopoietic system by self renewal of HSC. Deregulation of Wnt signaling, which is
normally tightly regulated, has been identified as an important step in leukemic transformation.
HSC differentiate into common myeloid progenitor cells (CMP) that gives rise to granulocyte
macrophage progenitors (GMP). GMP has been identified as the candidate leukemic stem cell
in the blast crisis stage of chronic myelogenous leukemia and has an active Wnt/ß-catenin
pathway (Jamieson et al., 2004). We observed reduction in active ß-catenin expression in EML
cells treated with high omega-3 FA relative to omega-6 FA, consistent with the fact that omega3 FAs have been shown to promote myeloid differentiation (Dupuis et al., 1997; Varney et al.,
2009).
We initially saw down-regulation of active ß-catenin protein in acute promyelocytic
leukemia, HL-60 cells upon exposure to high omega-3 FAs. It has been shown previously that
omega-3 FAs inhibit proliferation and induce differentiation in HL-60 cells which supports our
data (Finstad, 1994). Also, Wnt signaling is active in various cancers including myeloid
leukemia. Omega-3 FAs have been shown to inhibit omega-6 FA product, PGE2 and Wnt/ßcatenin signaling in hepatocellular and cholangiocarcinoma (Lim et al., 2008; Lim et al., 2009).
Up-regulation of Wnt signaling through epigenetic gene silencing of SFRPs is involved in
many forms of cancer. Wnt activation in stem cells requires PGE2 (product of omega-6 FAs),
and it has been shown recently that inhibition of PGE2 synthesis blocked Wnt-induced
alterations in HSC formation at the level of ß-catenin in vivo (Goeslling et al., 2009). These
initial findings indicated that omega-3 FA therapies aimed at disruption of the Wnt/β- catenin
pathways may be effective in the treatment and chemopreventive effects in leukemia.

87

Unfortunately, additional experiments aimed at understanding the mechanism and
effects of down-regulation of Wnt signaling, gave variable results. There was no significant
difference in the active ß-catenin expression in both EML and HL-60 omega-3 FA treated
compared to the omega-6 FA treated cells. We also measured active ß-catenin levels in the promonocytic U-937 cell line but did not see any difference in the cells exposed to omega-3 versus
omega-6 FAs. This inconsistency could be attributed to the fact that FAs exert their effects at
several levels, both through signal transduction pathways and on gene transcription. Since the
effect of FA on various cellular processes like differentiation and apoptosis depend upon the
concentration of FA and serum, exposure time and the cell model used (Rudolph et al., 2001). It
may be possible that inactivation of Wnt signaling by omega-3 FAs is a sensitive event which
requires a specific set conditions to be met. Another possibility could be that omega FAs exerts
their effects in the hematopoietic system through signal transduction pathways other than Wnt
ß-catenin pathway.
We used different methods to treat EML and HL-60 cells with various ratios of FA to
achieve our initial results but none of these were successful. Since, PUFA are not soluble in the
aqueous medium we tried sodium salts of FAs which have increased water solubility.
Moreover, FAs are carried within the body complexed to serum albumin and the FA: BSA
complexes are the main factors controlling FA availability for uptake (Melki et al., 1992).
Therefore, we serum starved EML cells to deplete any albumin present in the serum that might
bind to the free fatty acid and then treated the cells with FAs complexed to BSA.
We observed massive cell mortality in EML cells after exposure to either omega-3 or 6
FAs complexed with BSA, relative to the vehicle control. Several studies have reported the
cytotoxic effects of FA on different model systems. In one study, the authors demonstrated that
FA sensitive Burkitt lymphoma cell lines, Raji and Ramos, die by necrosis and apoptosis than
the FA resistant U-698 cell line upon incubation with EPA, respectively. These FA sensitive
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cell lines exhibit a 2 to 3 fold higher uptake rate of EPA than the FA resistant cell line.
Accumulation of TAG-rich lipid bodies was seen in Ramos cells incubated with 60 µm EPA
indicating a role for lipid bodies in regulation of the cellular suicide program. A high number of
TAG-rich bodies in Ramos cells, containing 2–3 molecules of EPA or DHA per glycerol
backbone, may cause marked changes in intracellular signal transduction and thereby initiate
apoptosis (Finstad et al., 2000).This response to in vitro fatty acid supplementation has
previously been reported for U937-1 cells (Finstad et al., 1998). In another study AA and EPA
were shown to induce apotosis and necrosis in a dose dependent manner in a murine
macrophage cell line, J774. When these cells were treated with FAs, they exhibited higher
granularity, suggesting accumulation of lipid droplets. The cytotoxic effects of the FAs were
suggested to be related to their ability to be incorporated into TAG (Martins et al., 2006).
Moreover, the variability in our data could be due to the heterogenous nature of EML
cells. It has been shown that EML cells can be separated into two different populations based
on CD34 expression. Levels of stem cell factor receptor (c-kit) are similar in both these
populations but they differ in growth characteristics and response to cytokines (Ye et al., 2005).
Another study demonstrated a broad spectrum of Sca-1 expression in EML cells which was
suggested to be the cause of clonal subpopulations in these cells. Most strikingly, the cells at
the extremes of the spectrum differed in their differentiation potential (Chang et al., 2008).
These studies indicate that EML cells are a heterogeneous population having phenotypic cellto-cell variability.
Our preliminary results suggested that the down-regulation of Wnt signaling upon
exposure to omega-3 FAs may occur in the hematopoietic precursor cell line EML and also
leukemic HL-60 cells. Unfortunately we could not reproduce these results. This nonreproducibility might be due to the fact that EML cells take into account only cell autonomous
factors. The stem cell niche, which is an important part of stem and progenitor cell biology, is
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not recapitulated in this model. Also, EML cells in culture are a heterogenous mixture of cells
with populations having different self renewal and differentiation potential. This heterogeneity
might have contributed to the variable responses seen in our studies.
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CHAPTER Five: Discussion and Conclusions
Hematopoiesis is maintained by a proper balance between self renewal and multipotent
differentiation of the HSC. Acute myelogenous leukemia (AML) is characterized by the
blockage in the differentiation of HSC while self renewal and proliferation is preserved.
Understanding the mechanisms involved in hematopoietic differentiation will help in developing
therapies against various hematological disorders including leukemia. To address this question I
investigated: (1) the involvement of Hsp90 in the regulation of Wnt signaling in HSCs cell line,
(2) the effect of omega-3 and 6 fatty acids treatments on the Wnt signaling in HSC cell line, (3)
YB-1 expression and function in early hematopoiesis and leukemic cells.

(1) The involvement of Hsp90 in the regulation of Wnt signaling in HSCs cell line
Hsp90 acts as a molecular chaperone to ensure the proper folding and refolding of
client proteins. Hsp90 clients are implicated in various signal transduction pathways and are
involved in the pathogenesis of cancer making it an attractive therapeutic target for cancer.
Previous studies in Drosophila demonstrated that inhibition of Hsp90 resulted in a
transdifferention event where the eye tissue became limb like outgrowth and was demonstrated
to occur through epigenetic mechamisms. This abnormal eye phenotype was associated with the
upregulated expression of wingless (Wg), a Drosophila homolog of Wnt, in the eye imaginal
discs. This study indicates that Hsp90 plays a critical role in determining the proper direction
of normal stem cell differentiation and might have implications in haematopoesis. In addition,
this study is particularly relevant in stem and progenitor cell biology as Wnt signaling regulates
the hematopoietic stem cell maintenance and self renewal (Kirstetter et al., 2006). Thus, the aim
of the part of my thesis was to determine whether Hsp90 inhibition would block the normal
HSC differentiation via up-regulating Wnt signaling.
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EML, a hematopoietic stem/progenitor cell line, was used as a model for my studies
(Tsai et al., 1994). In chapter 3, our preliminary data showed the transient up-regulation of Wnt
signaling upon Hsp90 inhibition in EML cells. This was an important result since it was the
first evidence of this interaction in a mammalian system and suggested the possibility of
phenotypic plasticity as seen in the Drosophila model upon Hsp90 inhibition. Phenotypic
plasticity is the ability to adapt to an unfavorable environment and this is particularly important
for evolution. Cancer cells show this plasticity, which provides them the ability to survive
under adverse conditions. Therefore, this increased adaptability could contribute to cancer
progression. However, we had reproducibility issues with these experiments.
Two separate studies have demonstrated the heterogeneity of the EML cell line. This
characteristic could be the reason behind the variability in our data. The published study
separated EML cells into two separate populations based on the CD34 expression. The CD34 +
population showed a growth response upon treatment with stem cell factor (SCF) while the
CD34- cells did not grow in SCF but responded to IL-3 treatment. This shift from the SCF
dependent growth to the requirement of IL-3 suggests an early differentiation event in the
CD34- population. Moreover, CD34
indicating that CD34

+

+

cells were Sca-1hi while CD34- cells were Sca-1lo

population possessed more stem cell characteristics (Ye et al., 2005).

The second study reported the broad spectrum of Sca-1 expression in EML cells that was
correlated with changes in differentiation potential. It is possible that these subpopulations
exhibit different responses upon Hsp90 inhibition (Chang et al., 2008). Therefore, we might
sort EML cells into different subpopulations based on the CD34 and Sca-1 expression and then
inhibit Hsp90 in the different populations. This will allow the analysis of the specific response
of Wnt signaling of each population upon Hsp90 inhibition.
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In our initial experiments, we saw a down-regulation of total ß-catenin levels in EML
cells after inhibiting Hsp90. Geldanamycin, a Hsp90 inhibitor, and its analogs have cytotoxic
effects on normal cells (Alcazar and Cid., 2009; Wu et al., 2010). Therefore, down-regulation
of total ß-catenin levels via geldanamycin treatment of EML cells might be toxic. Since the
effect of Hsp90 inhibition on Wnt signaling is based on the changes observed in the ß-catenin
expression, the overall down-regulation of ß-catenin expression due to toxic effects of
geldanamycin would adversely affect the interpretation of our data.
When we differentiated EML cells, active ß-catenin was inhibited in RA and GMCSF
treated cells but the undifferentiated EML cells pretreated with Hsp90 inhibitor did not show
any effect on the active ß-catenin levels. There was no significant difference in the level of
active ß-catenin in differentiated and undifferentiated EML cells upon Hsp90 inhibition.
It is possible that Hsp90 might not be involved in regulating Wnt signaling in the
mammalian hematopoietic system. In the Drosophila model, researchers reported that inhibition
of Hsp90 led to the up-regulation in Wg expression resulting in an abnormal eye phenotype
(Sollars et al., 2003). However, later analysis of this finding suggested the ectopic adhesion of
hemocytes under the eye imaginal disc to be a possible cause for the ectopic outgrowth rather
than up-regulated Wg expression in the peripodial membrane. This could be attributed to the
fact that hemocytes are involved in tissue remodeling (Ruden et al., 2003). Another possibility
is that the EML cell model takes into account only cell autonomous factors. The Wnt axis might
not be completely modeled in this system since Wnt is released from the niche cells and taken
up by the stem cells. Further, the EML cell line has been derived from mouse bone marrow by
the transfection of a dominant negative retinoic acid receptor. This blockage to hematopoietic
differentiation in the EML cells could be disrupting the normal Wnt signaling process.
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Thus, in this study we show the up-regulation of Wnt signaling in EML cells upon
Hsp90 inhibition. Unfortunately, this data was not reproducible. One contributing factor to this
lack of reproducibility could be that EML cells are known to have heterogenous populations.
Also, this in vitro model does not recapitulate the effects of the stem cell niche.
In the future, the role of Hsp90 regulation of Wnt signaling could be investigated in an
in vivo mouse model. For this study, mice could be treated with Hsp90 inhibitors such as
geldanamycin or 17-AAG and the effect of Hsp90 inhibition on normal hematopoesis measured
by colony formation assays and various differentiation markers. If Hsp90 inhibition
successfully blocks the normal hematopoietic differentiation, then the expression of active ßcatenin in HSC or progenitor cell populations would be determined using flow cytometry. Thus,
this study would determine the role of Hsp90 in regulating Wnt signaling during HSC
differentiation.

(2) The effect of omega-3 and 6 fatty acids on Wnt signaling in a HSC cell line
AML is characterized by problematic differentiation of HSC while self-renewal and
proliferation are preserved. Wnt signaling controls HSC self renewal and is active in various
cancers including acute and chronic myeloid leukemia (Wang et al., 2010; Jamieson et al.,
2004). Omega-3 FAs have been reported to promote myeloid differentiation by affecting
myeloid progenitor cell frequency (Dupuis et al., 1997; Varney et al., 2009). Also, omega-3
FAs have been demonstrated to induce differentiation in breast cancer (Wang et al., 2000) and
inhibit Wnt signaling in other cancers (Lim et al., 2008; Lim et al., 2009). Therefore, this
section of my thesis research analysed the effect of omega FA on Wnt signaling in the
hematopoietic system.
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In chapter 4, I showed that treatment of EML and HL-60 cells representing HSC and
myeloid leukemic cells respectively, with omega-3 FAs led to to the down-regulation of active
ß-catenin. In the hematopoietic precursor cell line, EML we found that high eicosapentanoic
acid (EPA) (omega-3) treated cells showed reduction in active ß-catenin levels relative to high
arachidonic acid (AA) (omega-6) treated cells. Similar results were observed in the human
promyelocyte leukemia cell line, HL-60. These results were exciting because they suggested
that omega-3 FA could have therapeutic potential in the treatment of leukemia by disrupting the
Wnt/β- catenin pathway.
Unfortunately, the data obtained in these initial experiments was not reproducible. One
possibility that I cited earlier in discussing the Hsp90 studies is the heterogeneous nature of the
EML cell culture. The presence of different subpopulations in EML cells which differ in their
growth characteristics and differentiation potential could lead to variable results (Ye et al.,
2005; Chang et al., 2008).
In addition, a report has shown that omega-3 (EPA) or omega-6 (AA) FAs treatment of
EML cells do not seem to have a significant difference on their differentiation profile (Varney
et al., 2011). In this study EML cells were differentiated into macrophage/granulocytic lineage
after exposure to omega-3 and omega-6 FAs. There was no effect of EPA or AA on the early
stem cell markers Sca-1 and CD117 upon differentiation of EML cells, though there was a
small increase in F4/80 (macrophage marker) after AA treatment. Further, there was no
difference in the viability or proliferation of cells treated with either EPA or AA. This suggests
that omega FAs does not have any effect on the proliferation and differentiation of early
differentiating EML cells. This could be the one of the reasons we did not observe any changes
in the Wnt signaling with omega FA treatment of these cells. In the same study, when effects of
omega FA were studied in an in vivo mouse model it was found that omega FA treatment
affected later stages of differentiation and not the stem cell stage. This suggests that to see the
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desired effects of omega-3 to omega-6 treatments in EML cells they might need to differentiate
for a longer duration.
Stem cell characteristics are known to be regulated by several factors which include
cell-cell interactions, growth factors, cytokines, and the physiochemical nature of the
environment in vivo. These components may only be replicated to a fairly limited extent in an
in vitro cell model; therefore the EML model gives a limited idea as to what effects FAs have in
vivo. Thus, the potential effect of omega FAs on hematopoiesis requires the investigation of a
mouse model.
Omega FAs can be fed to the mice in the diet as corn (omega-6) or canola oil (omega3) and its effects on ß-catenin accumulation in HSC and myeloid progenitors could be
quantified by flow cytometry. In addition, to further determine the effects of FA treatment on
Wnt signaling in hematopoietic stem and progenitor cells, these cells can be sorted by flow
cytometry using specific cell surface markers and the sorted cells cultured. Unphosphorylated
or active ß-catenin interacts with TCF/LEF transcription factors to activate the downstream
target genes (Mc Donald et al., 2006). Therefore, a reporter assay for the TCF/LEF can be
performed in these sorted HSC/progenitor cells as a measure of ß-catenin mediated
transcriptional activation. Thus, this study would confirm the effect of FA treatments on Wnt
signaling by functional activation of ß-catenin in addition to its accumulation in
HSC/Progenitor cells.

(3) YB-1 expression and function in early hematopoiesis and leukemic cells
YB-1 promotes cell proliferation through transcriptional regulation of various genes
involved in cell division. It also enhances cell growth by promoting both cell cycle progression
and DNA replication (Kohno et al., 2003). In addition it induces the expression of genes such
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as MMP-2 which are associated with invasion and metastasis (Cheng et al., 2002). Thus, YB-1
is implicated in cancer pathogenesis. YB-1 is reported to be involved in erythroid cell
development as it was shown to be highly expressed when erythroid cell maturation was
inhibited (Yokoyama et al., 2003a, b). Moreover, YB-1 expression was found to be higher in
the bone marrow samples of patients with MDS. Further, YB-1 expression was showed to be
higher specifically in the erythroid progenitors of MDS patients. Although YB-1 is reported to
be involved in erythropoesis its role and regulation in normal hematopoiesis is not known. Thus
part of my thesis research was to investigate the role and function of YB-1 expression in the
early hematopoiesis.
YB-1 mRNA and protein expression was high in the hematopoietic stem cell line,
EML, but was down-regulated during myeloid differentiation. Similar results were observed in
a previous cDNA microarray study that analyzed changes in gene expression during induced
myeloid differentiation of EML cells (Ma et al., 2002). Moreover, we found YB-1 to be highly
expressed in the lineage-/IL-7R-/c-kit+/Sca-1+ (LKS, enriched fraction for HSC) and lineage-/IL7R-/c-kit+/Sca-1- (myeloid progenitors) compared to in vivo differentiated granulocytes. This
finding is consistent with a previous study where YB-1 is highly expressed when erythroid cell
maturation was inhibited upon knockdown of GATA-1, an essential factor for erythroid cell
development. (Yokoyama et al., 2003b). YB-1 plays a role in embryogenesis and its expression
level correlates with the cell proliferation state (Lu et al., 2005). High levels of YB-1 are
present in human fetal tissues that represent more a stem cell stage of development, while YB-1
transcript is not detected or is expressed at very low level in many adult tissues (Spitkovsky et
al., 1992). These findings are consistent with our data that YB-1 is highly expressed in
HSC/progenitor cells while down-regulated in differentiating granulocytes. Our results with a
more well-defined cell population further suggest that YB-1 has a role in maintaining the stem
cell state.
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We also found that YB-1 was highly expressed in various myeloid leukemia cell lines,
supporting our hypothesis that YB-1 is involved in cancer progression.

This finding is

consistent with a previous study which reported increased expression of YB-1 in the bone
marrow of patients suffering from MDS (Lee et al., 2001). MDS is considered to be the
preleukemic state characterized by the ineffective production of mature blood cells due to
increased proliferation and reduced differentiation of HSC. MDS has a high predisposition to
transform into acute myelogenous leukemia. Knockdown of GATA-1, a transcription factor
required for erythropoieis in mice, leads to inhibition of erythroid differentiation. YB-1 is
highly expressed in the GATA-1 knockdown mouse. The mechanism behind YB-1 upregulation after GATA-1 knockdown is not known. However, these mice have a phenotype
similar to human MDS during early stages of life, and in later stages of life they develop acute
leukemia (Yokoyama et al., 2003 b). This suggests that YB-1 might be playing a role in the
development of MDS and leukemia.
To further investigate the biological effects of YB-1 expression in leukemia, we did
loss of function studies. For this we chose the high YB-1 expressing cell line, K-562, and
knocked down YB-1 using specific shRNA. Knock down of YB-1 resulted in a growth arrest
and induction of apoptosis in K562 cells. This effect was much more pronounced when we used
arsenic trioxide (As2O3). This compound has been shown to induce apoptosis in acute
promyelocytic cells (APL) and is being used a therapeutic agent in leukemia (Tang et al.,
1997). As2O3 treatment of K562 cells with YB-1 knockdown led to a statistically significant
reduction in cell proliferation. There was also a significant increase in the apoptotic population
of these cells. Down-regulation of YB-1 decreases cell viability and induces apoptosis in
multiple myeloma and melanoma cells (Schittek et al., 2007; Chatterjee et al., 2008).
Knockdown of YB-1 in the multi drug resistant K562/A02 cell line showed similar results and
is consistent with our data (Xu et al., 2009).
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Moreover, we found that treatment of As2O3 in K562 cells with down-regulation of
YB-1 resulted in their differentiation toward the megakaryocytic lineage (Figure 5.1). Since
impaired differentiation is the hallmark of myeloid leukemia, this finding has a significant
impact on our understanding of myeloid differentiation and might be exploited for therapy.
As2O3 exerts double effects on acute promyelocytic cells such as induction of apoptosis and
partial differentiation (Tang et al., 1997). We observed changes in the cellular morphology of
the YB-1 knockdown cells treated with As2O3. Subsequently, we determined the expression of
CD41a megakaryocytic/platelet marker. We found significant up-regulation of CD41a in YB-1
depleted K562 cells treated with As2O3. To confirm this data, we did ploidy analysis which
showed an increase in polyploidy in the As2O3 treated K562 cells containing reduced YB-1
levels. There was a significant increase in CD41a in untreated K562 cells when YB-1 was
reduced but we did not observe any significant change in cell morphology. This indicates that
down-regulation of YB-1 expression could initiate the differentiation process.
In chapter 2, we show for the first time the expression of YB-1 in the hematopoietic
stem/progenitor cells and its down-regulation during myeloid differentiation. Further, abnormal
YB-1 expression in leukemic cells contributes to leukemic properties by enhancing cell survival
and inhibiting cell differentiation (Figure 5.1).
We studied the expression and function of YB-1 in vitro using leukemia cell lines. Our
findings can be further verified by measuring YB-1 levels in patient samples from acute and
chronic myelogenous leukemia. This will help in translating our findings into humans and
determine whether YB-1 might be a useful prognostic marker in leukemia.
An important experiment to study the mechanism for the down-regulation of YB-1
during myeloid differentiation would be knocking down YB-1 in EML cells. It would be
interesting to see whether knockdown of YB-1 induces spontaneous differentiation in EML
cells as seen in K562 leukemic cells. If EML cells differentiate it will further corroborate that
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YB-1 plays role in early stage of hematopoietic differentiation at an early stage. It might be
possible that EML cells need a stimulant such as IL-3 for differentiation, which would imply
that YB-1 acts at a later stage of differentiation.
To investigate the potential effects of YB-1 gene knockdown in K562 cells a gene array
study could be beneficial. This assay will help in finding the putative target genes for YB-1.
The PI3K/Akt signaling pathway plays an important role in the proliferation,
differentiation and survival of hematopoietic cells. Constitutive activation of PI3K/Akt has been
demonstrated in AML patients and is associated with poor prognosis (Min et al., 2003; Kubota
et al., 2004). Akt has been shown to phosphorylate YB-1 leading to its nuclear translocation
and activation in breast cancer. Inhibition of the PI3K/Akt pathway suppresses nuclear
translocation of YB-1 in breast and ovarian cancer (Sutherland et al., 2005; Baski et al., 2006).
Since there are no direct inhibitors available for YB-1 we can inhibit it indirectly by using Akt
inhibitors in AML cell lines. Further, we could test whether these Akt inhibitors can reduce
YB-1 expression in a CML mouse model.
Wnt and Notch pathways play an important role in promoting self renewal in
hematopoietic stem and progenitor cells (Reya et al., 2003; Duncan et al., 2005). Examining
whether YB-1 is involved in the regulation of Wnt and Notch pathways in the hematopoietic
system would be of great interest. A recent study in breast cancer reported several members of
Wnt and Notch signaling pathways to be the targets of YB-1. Further, c-Kit, which is a receptor
expressed on the surface of HSC, was also identified as YB-1 target (Finkbeiner et al., 2009).
Mutations in the c-kit gene have been documented in AML and are associated with a poor
prognosis (Beghini et al., 2004). Thus, Wnt and Notch pathway elements and c-kit could be the
putative targets of YB-1 in the HSC/progenitor cells and in leukemia. Our previous two projects
focused on the regulation of Wnt signaling in the hematopoietic system by Hsp90 and omega
FAs. If Wnt signaling elements are targets of YB-1 it will be interesting to determine the
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association of YB-1 with Hsp90 or omega FAs.
In summary, my overall goal for these studies was to determine potential genes
involved in the regulation of hematopoietic differentiation. The first study initially suggested
Hsp90 might be involved in regulating Wnt signaling in the hematopoietic system. Our
preliminary data showed the transient activation of the canonical Wnt pathway in a
hematopoietic precursor cell line EML after the inhibition of Hsp90. Our second study initially
indicated that omega-3 FAs might affect Wnt signaling in the hematopoietic system and
leukemic cells. These results had great potential in increasing our understanding of how Hsp90
and omega FAs regulate Wnt signaling in the hematopoietic system. Unfortunately, further
progress in both of these studies was marred by the variability in repeated experiments.
However in our third study we have identified YB-1 as a marker in leukemia and that is
responsible for HSC maintenance, making it an attractive therapeutic target. We show high YB1 expression in the hematopoietic stem cell line EML, as well as in the HSC and myeloid
progenitors from mouse bone marrow. We found down-regulation of YB-1 expression during
myeloid differentiation in EML cells. Abnormal YB-1 expression was observed in myeloid
leukemic cell lines. In addition, increased expression of YB-1 in leukemic cells contributes to
the leukemic cell properties by stimulating proliferation, promoting cell survival and blocking
differentiation. Since inhibition of YB-1 in leukemic cells can induce differentiation it is an
attractive target for the development of new therapies for leukemia.
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Figure 5.1 Model for the expression and function of YB-1 in normal and leukemic cells.
Hematopoietic stem cells (HSCs) have the ability to self renew and give rise to common
myeloid progenitors (CMPs). CMP further differentiates to produce mature myeloid cells.
Blockage in the terminal differentiation of HSCs and CMPs can result in myeloid leukemia.
YB-1 is highly expressed in the HSCs and early myeloid progenitors relative to the
differentiated myeloid cells. Knockdown of YB-1 expression followed by treatment of arsenic
trioxide (As2O3) in K562 cells resulted in their differentiation toward the megakaryocytic
lineage. Thus, increased expression of YB-1 contributes to the leukemic cell properties by
promoting cell survival and inhibition of differentiation.
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